Compound with kinase inhibition activity

By designing and synthesizing FLT3 kinase inhibitor compounds with specific structures, the problems of poor efficacy and significant toxic side effects of existing therapeutic drugs have been solved, enabling effective treatment of diseases such as acute myeloid leukemia and providing a safer treatment option.

CN118955502APending Publication Date: 2024-11-15CYTOSINLAB THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411031073.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-02-08
Filing Date
2021-07-22
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing treatments for malignant tumors such as acute myeloid leukemia are not very effective and have significant toxic side effects. There is a need to develop novel FLT3 kinase inhibitors to effectively regulate abnormal kinase activity.

Method used

A novel class of FLT3 kinase inhibitor compounds with specific aza-aryl ring structures were designed and synthesized. These compounds inhibit the activity of FLT3 enzymes by binding to them. The class includes various pharmaceutically acceptable salt, racemic, and isomer forms, which are used to prepare pharmaceutical compositions for the treatment of related diseases.

Benefits of technology

This compound exhibits excellent kinase inhibitory activity, which can effectively treat or prevent diseases caused by FLT3 kinase abnormalities, such as acute myeloid leukemia, reduce toxic side effects, and provide more effective treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955502A_ABST
    Figure CN118955502A_ABST
Patent Text Reader

Abstract

The invention provides a compound with kinase inhibition activity, and particularly provides a compound with a structure as shown in a formula (II) in the specification. The compound disclosed by the invention has good inhibitory activity on various kinases (such as ALK, AXL, EGFR and FLT3), so that the compound can be used for preparing pharmaceutical compositions (such as acute myeloid leukemia and the like) for treating kinase activity related diseases. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is application number 202180058999.3, the applicant is Shanghai Sailan Biotechnology Co., Ltd., and the name of the invention is a divisional application of the invention application for a class of compounds with kinase inhibitory activity. Technical Field

[0002] The present invention relates to the field of medicinal chemistry and medicine, and in particular to a class of FLT3 compounds, a preparation method thereof, and the use thereof in treating diseases associated with abnormal FLT3 activity or expression, such as acute myeloid leukemia. Background Art

[0003] The occurrence and development of malignant tumors is a complex process. Traditional therapeutic drugs are mainly divided into several categories, such as alkylating agents, antimetabolites, natural products and antibiotics. The disadvantages of these drugs are that the efficacy is not obvious and the side effects are large. At present, small molecule kinase inhibitors are an interesting field as potential cancer therapies. Protein kinases are catalysts that play a key role in almost every aspect of cell biology and biochemistry. These enzymes produce signal modules that regulate cell cycle progression, proliferation, programmed cell death (apoptosis), cytoskeletal function, movement, differentiation, development, transcription and translation. Protein kinases have many roles, and careful regulation of them is crucial because abnormal activities may cause cancer, cardiovascular disease, inflammation and neurological disorders. The dysregulation, overexpression and mutation of protein kinases play a causal role in the pathogenesis of human diseases, so these enzymes are attractive drug targets. Growth factor receptors with protein tyrosine kinase (PTKs) activity are called receptor tyrosine kinases. Protein receptor tyrosine kinases are a class of tightly regulated enzymes, and abnormal activation of different members of the family is one of the hallmarks of cancer. FLT3 belongs to the receptor tyrosine kinase family together with receptors such as KIT, FMS, and platelet-derived growth factor receptor (PDGFR), which play an important role in hematopoietic regulation.

[0004] FLT3 (FMS-like tyrosine kinase-3) is a specific cytokine receptor expressed on hematopoietic stem cells. It has the functions of regulating the survival and growth of hematopoietic stem cells, maturation of dendritic cells, and maintaining the homeostasis of regulatory T cells. About 30% of patients with acute myeloid leukemia (AML) have FLT3 gene mutations, mainly including FLT3 internal tandem duplication (FLT3-ITD) and FLT3 tyrosine kinase domain point mutation (FLT3-TKD). FLT3-ITD mutations lead to constitutive, ligand-independent activation of tyrosine kinase function, which is known to have a poor prognosis for patient survival. It accounts for about 25% of AML patients, and FLT3-TKD accounts for about 5% to 10%. FLT3 can dimerize and undergo autophosphorylation upon ligand binding, thereby initiating multiple intracellular signaling programs. In vitro experiments have found that FLT3 mutations can promote cell proliferation and inhibit cell apoptosis through MAPK, PI3K / AKT / Mtor and STAT5 downstream transduction pathways. The high incidence of FLT3 mutation and poor prognosis suggest that it may be an important target for AML treatment.

[0005] In summary, there is an urgent need in the art to develop novel FLT3 kinase inhibitors. Summary of the invention

[0006] The purpose of the present invention is to provide a novel FLT3 kinase inhibitor.

[0007] The first aspect of the present invention provides a compound as shown in the following formula I, or a pharmaceutically acceptable salt or deuterated product thereof:

[0008]

[0009] in, The ring is an aza 5-6 membered heteroaromatic ring, and is a 5-6 membered aromatic ring or heteroaromatic ring, and the

[0010] Ring and The rings together form a 9-10 membered heteroaromatic ring;

[0011] Ra is selected from the following group: H, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), substituted or unsubstituted 5-9 membered heteroaromatic ring (including monocyclic or condensed ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 3-8 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen (which is a saturated or partially unsaturated heterocycle, preferably a substituted or unsubstituted C3-C6 cycloalkyl, a substituted or unsubstituted 3-6 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen), or substituted or unsubstituted -[L] m -H group; wherein each L is independently selected from the following group: -CH2-, -O-, -NH- or -S-;

[0012] m is selected from the group consisting of 1, 2, 3, 4, 5 or 6;

[0013] U is selected from the group consisting of a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-;

[0014] Rc is selected from the following groups: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), substituted or unsubstituted 3-8 membered heterocycle (saturated or partially unsaturated, including monocyclic, condensed, bridged or spirocyclic) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C6-C 10 aryl, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, or a substituted or unsubstituted -[L] m -H group; wherein each L is independently selected from the following group: -CH2-, -O-, -NH- or -S-;

[0015] Re is selected from the group consisting of halogen, -NHR, -OR, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-NH-, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), or substituted or unsubstituted -[L] m -H group; wherein each L is independently selected from the following group: -CH2-, -O-, -NH- or -S-;

[0016] W is selected from the group consisting of H, -NHR, -OR, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 4-15 membered heterocyclic ring (saturated or partially unsaturated ring, including monocyclic, condensed, bridged or spirocyclic ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring (including monocyclic or condensed ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl (including single ring, condensed ring, bridged ring or spiro ring), substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide;

[0017] The W group is substituted by at least one group having a -MA structure, and the M is selected from the following group: a chemical bond, or -CHR-, a carbonyl group, S, O, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-;

[0018] The A is selected from the following groups: H, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 4-12 membered heterocyclic ring (including monocyclic, fused polycyclic, bridged or spirocyclic ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring (including monocyclic or fused ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C4 alkyl-SO-;

[0019] In the group A, the substitution refers to substitution by one or more groups selected from group B, and the group B includes: H, halogen, =O, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 3-12 membered (preferably 5-7 membered) heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C4 alkyl-SO-; and in the group B, the substitution refers to substitution by one or more R groups;

[0020] R is a group selected from the following group: H, halogen, cyano, amino, nitro, hydroxyl, mercapto, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C4 alkyl-SO-;

[0021] Unless otherwise specified, in the above formulae, the substitution refers to the substitution of hydrogen atoms on the corresponding groups by one or more substituents selected from the group consisting of deuterium, tritium, halogen, hydroxyl, carboxyl, mercapto, benzyl, C1-C 12 Alkoxycarbonyl, C1-C6 aldehyde, amino, C1-C6 amide, nitro, cyano, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C3-C8 cycloalkyl, C2-C 10 Alkenyl, C1-C6 alkoxy, C1-C6 alkyl-amino, C6-C 10aryl, five-membered or six-membered heteroaryl, five-membered or six-membered non-aromatic heterocyclic group, -O-(C6-C 10 aryl), -O-(five-membered or six-membered heteroaryl), C1-C 12 Alkylaminocarbonyl, unsubstituted or halogenated C2-C 10 Acyl, sulfonyl (-SO2-OH), phosphoryl (-PO3-OH), unsubstituted or halogenated C1-C4 alkyl-S(O)2-, unsubstituted or halogenated C1-C4 alkyl-SO-.

[0022] In another preferred embodiment, the compound of formula I has a structure shown in the following formula II:

[0023]

[0024] Wherein, X, Y and Z are each independently selected from the following group: N or CR.

[0025] In another preferred embodiment, the compound of formula I has a structure shown in the following formula IIa:

[0026]

[0027] Wherein, the W ring is selected from the following group: substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl; wherein, in the W group, the substitution refers to substitution by one or more groups selected from group A.

[0028] In another preferred embodiment, the W ring is a group selected from the following groups: a substituted or unsubstituted 4-7 membered heterocyclic ring, a substituted or unsubstituted 5-6 membered heteroaromatic ring, a substituted or unsubstituted 9-10 membered fused bicyclic heteroaromatic ring, a substituted or unsubstituted phenyl group, or a substituted or unsubstituted C3-C6 cycloalkyl group.

[0029] In another preferred embodiment, the W ring is a substituted or unsubstituted cyclic structure selected from the following group: phenyl, cyclopentyl, cyclohexyl,

[0030]

[0031] In another preferred embodiment, the compound of formula I has a structure shown in the following formula III:

[0032]

[0033] wherein the A ring is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl; M is selected from the following group: a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-.

[0034] In another preferred embodiment, the compound of formula I has a structure as shown below:

[0035]

[0036] in,

[0037] Rf is selected from the group consisting of H, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy;

[0038] t is 0, 1, 2, 3, or 4;

[0039] The A ring is selected from the following groups: a substituted or unsubstituted 5-12 membered saturated ring (including a spiro ring and a bridged ring), a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 The aromatic group has at least one heteroatom selected from N or O on the ring.

[0040] In another preferred embodiment, at least one of the Rf is located at the meta position of the connection site between the benzene ring and the mother nucleus.

[0041] In another preferred embodiment, the compound of formula I has a structure as shown below:

[0042]

[0043] in,

[0044] Rf is selected from the group consisting of H, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy;

[0045] t is 0, 1, 2, 3, or 4;

[0046] L is N or CH;

[0047] The A ring is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C6-C 10 Aryl.

[0048] in, When the nitrogen atom on NH is the attachment site, the NH is N (ie, the hydrogen atom on NH is lost to form the attachment site).

[0049] In another preferred embodiment, the compound of formula I has a structure shown in the following formula IV:

[0050]

[0051] wherein the A ring is selected from the following groups: a substituted or unsubstituted 4-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl;

[0052] M is selected from the following group: a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-;

[0053] Ring B is selected from the following group: a substituted or unsubstituted 4-12 membered heterocyclic ring (including a monocyclic ring, a fused polycyclic ring, a bridged ring or a spirocyclic ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted C3-C 12 Carbon ring;

[0054] V is selected from the following group: a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-.

[0055] In another preferred embodiment, the compound of formula I has a structure as shown below:

[0056]

[0057] Wherein, Rg is selected from the following group: halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy;

[0058] The B ring is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring (including a monocyclic ring, a fused polycyclic ring, a bridged ring or a spirocyclic ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted C3-C 12 Carbon ring;

[0059] u is 0, 1, 2, 3, or 4.

[0060] In another preferred embodiment, the compound of formula I has a structure as shown below:

[0061]

[0062] Wherein, Rg is selected from the following group: halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy;

[0063] u is 0, 1, 2, 3, or 4.

[0064] In another preferred embodiment, the A ring has at least one substituent G, and the G group is selected from the following groups: amino, =O, a substituted or unsubstituted 4-7 membered heterocycle containing 1-3 heteroatoms selected from oxygen and nitrogen, a substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 an ester group, or a substituted or unsubstituted C1-C6 amide group.

[0065] in, When the nitrogen atom on NH is the attachment site, the NH is N (ie, the hydrogen atom on NH is lost to form the attachment site).

[0066] In another preferred embodiment, the compound of formula I has a structure selected from the following group:

[0067]

[0068] In another preferred embodiment, the W is selected from the following group:

[0069] In another preferred embodiment, the W is selected from the following group:

[0070] In another preferred embodiment, the Rc is selected from the following group:

[0071]

[0072] In another preferred embodiment, the URc is selected from the following group:

[0073]

[0074] In another preferred embodiment, Re is selected from the following group: amine, substituted or unsubstituted C1-C6 alkyl-NH-.

[0075] The second aspect of the present invention provides a pharmaceutical composition, which contains a therapeutically effective amount of a compound of formula I as described in the first aspect of the present invention, its pharmaceutically acceptable salts, racemates, R-isomers and S-isomers, stereoisomers or tautomers, and one or more pharmaceutically acceptable carriers, excipients, adjuvants, auxiliary materials and / or diluents.

[0076] The third aspect of the present invention provides a use of a compound of formula I as described in the first aspect of the present invention, its racemate, R-isomer, S-isomer or pharmaceutically acceptable salt in the preparation of a medicament for treating or preventing a disease associated with abnormal gene level or abnormal expression of a kinase selected from the following group (such as corresponding nucleic acid mutation, deletion, or ectopic or fusion or overexpression of the kinase): FLT3, ALK, RET, ROS, AXL, EGFR.

[0077] In another preferred embodiment, the disease is selected from the following group: acute myeloid leukemia, neurofibromatosis type I, multiple myeloma, malignant glioma, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, cervical cancer, lymphoma, bone metastasis, hormone-refractory prostate cancer, hormone-dependent prostate cancer, thyroid tumor, medullary thyroid carcinoma, mesothelioma, glioblastoma, bone metastasis, Merkel cell carcinoma, genitourinary tract tumors, Merkel cell carcinoma, bladder cancer, papillary thyroid carcinoma, breast cancer, soft tissue sarcoma, glioma, neuroendocrine tumor, Renal cell carcinoma, advanced solid tumors, undifferentiated astrocytic carcinoma, gastrointestinal stromal tumors, Hippel-Lindau syndrome, small cell lung cancer, pancreatic cancer, pancreatic endocrine cancer, central nervous system tumors, metastatic renal cancer, endometrioid carcinoma, endometrioid adenocarcinoma, lung cancer, colorectal cancer, ovarian cancer, rhabdomyosarcoma, melanoma, retinoblastoma, central and peripheral nervous system tumors, acute leukemia, chronic leukemia, bile duct cancer, bronchial cancer, esophageal cancer, testicular cancer, skin cancer, oral cancer, neuroblastoma, anaplastic large cell lymphoma.

[0078] In another aspect, the present invention provides a conjugate, wherein the conjugate is obtained by connecting the compound of the present invention and a biological small molecule or a monoclonal antibody through a chemical bond.

[0079] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION

[0080] Through extensive and in-depth research, the inventors unexpectedly discovered for the first time a class of compounds with kinase inhibitory activity (such as FLT3, ALK, AXL, EGFR, etc.), and completed the present invention on this basis.

[0081] the term

[0082] In the present invention, the halogen is F, Cl, Br or I.

[0083] In the present invention, unless otherwise specified, the terms used have the general meanings known to those skilled in the art. In the present invention, if not otherwise specified, all chemical formulae are intended to cover any possible optical or geometric isomers (e.g., R-type, S-type or racemate, or cis-trans isomers of olefins, etc.).

[0084] In the present invention, the term "C1-C6 alkyl" refers to a straight or branched alkyl group having 1 to 6 carbon atoms, including but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl and hexyl, etc.; preferably ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl.

[0085] In the present invention, the term "C1-C6 alkoxy" refers to a straight or branched alkoxy group having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy and the like.

[0086] In the present invention, the term "C2-C6 alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including but not limited to ethenyl, propenyl, butenyl, isobutenyl, pentenyl and hexenyl.

[0087] In the present invention, the term "C2-C6 alkynyl" refers to a straight or branched alkynyl group having 2 to 6 carbon atoms and containing one triple bond, including but not limited to ethynyl, propynyl, butynyl, isobutynyl, pentynyl and hexynyl.

[0088] In the present invention, the term "C3-C10 cycloalkyl" refers to a cyclic alkyl group having 3 to 10 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and cyclodecyl, etc. The terms "C3-C8 cycloalkyl", "C3-C7 cycloalkyl", and "C3-C6 cycloalkyl" have similar meanings.

[0089] In the present invention, the term "C3-C10 cycloalkenyl" refers to a cyclic alkenyl group having 3 to 10 carbon atoms in the ring, including but not limited to cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl and cyclodecyl, etc. The term "C3-C7 cycloalkenyl" has a similar meaning.

[0090] In the present invention, the term "C1-C12 alkoxycarbonyl" refers to an alkoxycarbonyl group having 1 to 12 carbon atoms in the alkyl chain, including but not limited to methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl and the like.

[0091] In the present invention, the term "C1-C12 alkylaminocarbonyl" refers to an alkylaminocarbonyl group having 1 to 12 carbon atoms in the alkyl chain, including but not limited to methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, tert-butylaminocarbonyl, benzylaminocarbonyl, dimethylaminocarbonyl and the like.

[0092] In the present invention, the term "C5-C9 furanosyl" refers to a furanosyl group having 5 to 9 carbon atoms, wherein the 1-position of the sugar group is connected to the main chain, including but not limited to ribofuranosyl, deoxyribofuranosyl, galactofuranosyl and the like.

[0093] In the present invention, the term "C5-C9 pyranosyl" refers to a pyranosyl group having 5 to 9 carbon atoms, wherein position 1 of the saccharide group is connected to the main chain, including but not limited to pyranosyl glucopyranosyl, pyranosyl glucuronide, pyranosyl rhamnosyl, pyranosyl galactosyl, pyranosyl mannosyl, pyranosyl xylopyranosyl and the like.

[0094] In the present invention, the term "aromatic ring" or "aryl" has the same meaning, preferably "aryl" is "C6-C12 aryl" or "C6-C10 aryl". The term "C6-C12 aryl" refers to an aromatic ring group having 6 to 12 carbon atoms without heteroatoms in the ring, such as phenyl, naphthyl, etc. The term "C6-C10 aryl" has a similar meaning.

[0095] In the present invention, the term "aromatic heterocycle" or "heteroaryl" has the same meaning and refers to a heteroaromatic group containing one to multiple heteroatoms. The heteroatoms referred to here include oxygen, sulfur and nitrogen. For example, furanyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.

[0096] In the present invention, the term "3-12 membered heterocyclic group" refers to a saturated or unsaturated 3-12 membered ring group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen in the ring, such as dioxolanyl, etc. The term "3-7 membered heterocyclic group" has a similar meaning.

[0097] In the present invention, the term "substituted" refers to one or more hydrogen atoms on a specific group being replaced by a specific substituent. The specific substituent is a substituent described above, or a substituent appearing in the embodiments. Unless otherwise specified, a substituted group may have a substituent selected from a specific group at any substitutable site of the group, and the substituent may be the same or different at each position. A cyclic substituent, such as a heterocycloalkyl, may be connected to another ring, such as a cycloalkyl, to form a spiro bicyclic system, for example, two rings having a common carbon atom. It will be appreciated by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically feasible. The substituents include, but are not limited to, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 3- to 12-membered heterocyclic groups, aryl, heteroaryl, halogen, hydroxyl, carboxyl (-COOH), C1-8 aldehyde, C2-10 acyl, C2-10 ester, C1-C12 alkoxycarbonyl, amino, alkoxy, C1-10 sulfonyl, etc.

[0098] FLT3 inhibitor compounds

[0099] The present invention provides a class of compounds having FLT3 inhibitory activity:

[0100]

[0101] wherein each group has the same meaning as described above.

[0102] In the present application, the preferred compounds are selected from the following Table 1:

[0103] Table 1

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115]

[0116]

[0117]

[0118]

[0119]

[0120]

[0121]

[0122]

[0123]

[0124]

[0125]

[0126] Among them, 162 and 163 are But the absolute configuration is unknown, 164 and 165 are But the absolute configuration is unknown. 284 and 285 are But the absolute configuration is unknown.

[0127] Pharmaceutical compositions and methods of administration

[0128] Since the compounds of the present invention have excellent kinase inhibitory activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate related diseases caused by abnormal activity or expression of kinases (such as FLT3).

[0129] The pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, and more preferably, contains 5-200 mg of the compound of the present invention per dose. Preferably, the "one dose" is a capsule or tablet.

[0130] "Pharmaceutically acceptable carrier" refers to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as ), wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0131] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administrations include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0132] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0133] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.

[0134] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.

[0135] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0136] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances, and the like.

[0137] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0138] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0139] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds. In some preferred embodiments, the compounds of the present invention can be administered together with other small molecule compounds to form PROTAC, or together with other macromolecular compounds such as monoclonal antibodies to form ADC.

[0140] When using the pharmaceutical composition, a safe and effective amount of the compound of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage, and for a person weighing 60 kg, the daily dosage is usually 1 to 2000 mg, preferably 5 to 500 mg. Of course, the specific dosage should also take into account factors such as the route of administration and the health status of the patient, which are all within the skill range of a skilled physician.

[0141] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0142] The definitions of each abbreviation are as follows:

[0143]

[0144]

[0145] The raw materials can be obtained from commercial sources or prepared by methods known or disclosed in the art.

[0146] The purification of intermediates and compounds is carried out by normal phase or reverse phase chromatography or conventional chemical experimental operations such as recrystallization. Normal phase chromatography is pre-filled with silica gel chromatographic columns or preparative thin layer chromatography. Silica gel chromatographic columns are mainly glass columns or rapid preparative chromatographs. The mobile phase of normal phase chromatography is selected and proportioned from petroleum ether / ethyl acetate, dichloromethane / methanol or other suitable solvents for elution. Reverse phase preparative liquid chromatography uses a C18 column, and is carried out using a preparative liquid chromatograph or a rapid preparative chromatograph, 214nM and 254nM or preparative liquid chromatography-mass spectrometry instrument detection, and uses water / acetonitrile containing 0.1% hydrochloric acid, water / acetonitrile, water / acetonitrile containing 0.1% ammonium bicarbonate, water / acetonitrile containing 0.1% formic acid, 0.1% ammonia water / acetonitrile, 0.1% trifluoroacetic acid water / acetonitrile or other suitable solvent systems as mobile phases for gradient elution.

[0147] The structures of intermediates and compounds were characterized by nuclear magnetic resonance (NMR) and mass spectrometry (LCMS). The NMR spectrometer used for NMR was Bruker Ascend 400 or Varian 400 or ZKNJ BIXI-1 300MHz or Bruker Avance III 400MHz or Bruker AVANCE Neo 400MHz. The solvents used were deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol or other deuterated solvents as noted. Spectral data were reported in the mode: chemical shift δ (peak splitting number, coupling constant J (Hz), number of hydrogens). Tetramethylsilane was used as an internal standard for chemical shift, and its chemical shift was set to zero (δ, 0ppm). The meanings of some abbreviations are: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad peak).

[0148] Representative methods for liquid chromatography-mass spectrometry (LCMS) in the structural characterization of intermediates and compounds are as follows:

[0149] Method 1: Agilent LC1260 system coupled to a 6120 single quadrupole mass spectrometer

[0150] Column: Waters CORTECS C-18, 2.7μm, 4.6*30mm. Solvent A: 0.05% formic acid in water, solvent B: 0.05% formic acid in acetonitrile, 5% acetonitrile to 95% acetonitrile in one minute, hold for one minute, total 2.5 minutes; flow rate: 1.8mL / min; column temperature 40℃.

[0151] Column: XSelect CSH C18, 3.5μm, 4.6*50mm. Solvent A: 0.05% ammonia solution, solvent B: 0.05% ammonia in acetonitrile solution, 5% acetonitrile to 95% acetonitrile within one minute, hold for one minute, a total of 2.5 minutes; flow rate: 1.8mL / min; column temperature 40℃.

[0152] Method 2: Agilent LC / MSD 1200 system coupled with a quadrupole mass spectrometer. Column: ODS2000 (50×4.6 mm, 5 μm) (ES (+) or (-) ionization mode), temperature 30°C; flow rate 1.5 mL / min.

[0153] General method: Synthesis of compound 8

[0154] Example 1: 3-ethyl-8-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine trihydrochloride (Compound 8)

[0155]

[0156]

[0157] Step 1: Dissolve 1-benzyl-4-piperidone (5.00 g, 26.5 mmol) and 1-tert-butyloxycarbonylpiperazine (5.41 g, 29.1 mmol) in dichloromethane (100 mL), add acetic acid (2.38 g, 39.7 mmol), and stir at room temperature for 5 hours. Then add sodium triacetoxyborohydride (22.4 g, 106 mmol) to the solution in batches and stir at room temperature overnight. The reaction solution is concentrated, water (100 mL) is added to the resulting residue, and the pH value is adjusted to 10 with 5% sodium hydroxide. Extract with ethyl acetate three times (50 mL × 3), combine the organic phases, wash with saturated brine (50 mL), dry over anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, and purify the residue by C18 reverse phase chromatography (from water containing 50% acetonitrile to water containing 90% acetonitrile) to obtain yellow solid 4-(1-benzylpiperidin-4-yl)piperazine-1-carboxylic acid tert-butyl ester (5.80 g, yield 61%). MS: 360.4 [M+H] + .

[0158] Step 2: Dissolve tert-butyl 4-(1-benzylpiperidin-4-yl)piperazine-1-carboxylate (5.80 g, 16.1 mmol) in methanol (100 mL) and add 10% palladium on carbon (1.5 g). The mixture was stirred at 50°C under hydrogen (50 psi) and reacted overnight. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure to obtain tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (4.15 g, yield 96%) as a white solid. 1 HNMR (300MHz, CDCl3): δ3.44-3.41(m,4H),3.17-3.13(m,2H),2.63-2.58(m,2H),2.5 5-2.49(m,4H),2.41-2.31(m,1H),1.82-1.78(m,2H),1.46(s,9H),1.43-4.33(m,2H).

[0159] Step 3: Dissolve 1-fluoro-2-methoxy-4-nitrobenzene (2.00 g, 11.7 mmol) and tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (3.46 g, 12.9 mmol) in N,N-dimethylformamide (30 mL), and add potassium carbonate (3.23 g, 23.4 mmol). The mixture was stirred at 100 ° C for 2 hours. The reaction was cooled to room temperature, water (100 mL) was added, and ethyl acetate was extracted twice (30 mL × 2), and the organic phases were combined. The organic phase was washed twice with saturated brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow solid tert-butyl 4-(1-(2-(2-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (4.90 g, yield 99%). 421.0 [M+1] + .

[0160] Step 4: Dissolve tert-butyl 4-(1-(2-(2-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (4.90 g, 11.7 mmol) in methanol (50 mL) and add 10% palladium on carbon (0.5 g). The mixture was stirred at 50°C under hydrogen (hydrogen balloon) overnight. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure to give tert-butyl 4-(1-(4-amino-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (4.50 g, yield 99%) as a purple solid.

[0161] 1HNMR (400MHz, CDCl3): δ6.77 (d, J = 8.4Hz, 1H), 6.26-6.23 (m, 2H), 3.81 (s, 3H), 3.50-3.38 (m, 8H),2.55-2.54(m,2H),2.50-2.47(m,2H),2.45-2.37(m,1H),1.83-1.78(m,4H),1.46(s,9H).

[0162] Step 5: Dissolve tert-butyl 4-(1-(4-amino-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (3.40 g, 8.72 mmol) and diiodomethane (7.00 g, 26.1 mmol) in acetonitrile (100 mL), and add isoamyl nitrite (1.53 g, 13.1 mmol). The mixture was stirred at 80 ° C for 4 hours under nitrogen protection. The reaction temperature was cooled to room temperature and concentrated under reduced pressure. Dichloromethane (30 mL), water (20 mL), and saturated sodium carbonate solution (10 mL) were added to the residue. The mixed solution was extracted three times with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 2:1 to ethyl acetate) to give brown solid tert-butyl 4-(4-(4-iodo-2-methoxyphenyl)cyclohexyl)piperazine-1-carboxylate (1.85 g, yield 42%). 1 H NMR (300MHz, CDCl3) δ7.21(dd,J=8.1,1.8Hz,1H),7.09(d,J=1.5Hz,1H),6.65(d,J=8.4Hz,1H),3.84(s,3H),3.52-3 .48(m,2H),3.46-3.42(m,4H),2.56-2.47(m,6H),2.42-2.38(m,1H),1.87-1.74(m,4H),1.46(s,9H).MS:502.5[M+H] + .

[0163] Step 6: Dissolve tert-butyl 4-(4-(4-iodo-2-methoxyphenyl)cyclohexyl)piperazine-1-carboxylate (1.85 g, 3.69 mmol) in N,N-dimethylformamide (100 mL), add diboric acid pinacol ester (1.13 g, 4.43 mmol), potassium acetate (1.09 g, 11.1 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (135 mg, 0.17 mmol). The mixture was stirred at 100 ° C for 5 hours under nitrogen protection. The reaction mixture was cooled to room temperature, poured into water (100 mL), and saturated sodium carbonate solution (10 mL) was added. The mixed solution was extracted with ethyl acetate three times (30 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 1:1 to ethyl acetate) to obtain a yellow solid 4-

[0164] (1-(2-Methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)-1-tert-butyloxycarbonylpiperazine (Intermediate A, 1.30 g, yield 70%). 1 H NMR (300MHz, CDCl3) δ7.39(d,J=7.8Hz,1H),7.25(s,1H),6.93(d,J=7.8Hz,1H),3.91(s,3H),3.64-3.60(m,2H),3.4 6-3.43(m,4H),2.62-2.55(m,6H),2.50-2.41(m,1H),1.89-1.76(m,4H),1.47(s,9H),1.33(s,12H).MS:502.6[M+H] + .

[0165] Step 7: Dissolve 5-bromo-2-chloropyridine-3,4-diamine (5.00 g, 22.5 mmol) and ethyl 2-oxobutyrate (3.51 g, 27.0 mmol) in ethanol (100 mL), and add acetic acid (0.2 mL). The mixture was stirred at 90 ° C for 36 hours under nitrogen protection. The reaction was cooled to 50 ° C, filtered, and the filter cake was washed with ethanol (10 mL × 3). The filtrate was concentrated under reduced pressure to obtain a residue, which was dissolved in ethanol (20 mL), heated to reflux for 10 minutes, then cooled to 50 ° C, filtered, and the filter cake was washed with ethanol (10 mL × 2). After drying, a yellow solid 8-bromo-5-chloro-3-ethylpyrido [3,4-b] pyrazine-2 (1H) -one (4.1 g, yield 63%) was obtained. 1H NMR (400MHz, DMSO-d6) δ12.32(br s,1H),8.50(s,1H),2.86(q,J=7.6Hz,2H),1.25(t,J=7.6Hz,3H).

[0166] Step 8: 8-bromo-5-chloro-3-ethylpyrido[3,4-b]pyrazine-2(1H)-one (3.10 g, 10.7 mmol) was suspended in dichloromethane (50 mL), and 5 drops of N,N-dimethylformamide and oxalyl chloride (5.46 g, 43.0 mmol) were added. The mixture was stirred at 40°C under nitrogen protection overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Dichloromethane (50 mL), water (30 mL), and saturated sodium carbonate solution (10 mL) were added to the residue. The mixture was extracted with dichloromethane five times (30 mL×5). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow solid 8-bromo-2,5-dichloro-3-ethylpyrido[3,4-b]pyrazine (2.0 g, yield 61%). 1 H NMR (300MHz, DMSO-d6) δ8.91 (s, 1H), 3.20 (q, J = 7.2Hz, 2H), 1.39 (t, J = 7.2Hz, 3H).

[0167] Step 9: Suspend tetrahydropyran-4-amine (1.35 g, 9.77 mmol) in ethanol (20 mL), add N,N-diisopropylethylamine (2.52 g, 19.5 mmol), and stir at room temperature for half an hour. Suspend 8-bromo-2,5-dichloro-3-ethylpyrido[3,4-b]pyrazine (2.00 g, 6.51 mmol) in ethanol (30 mL), add N,N-diisopropylethylamine (1.68 g, 13.0 mmol), and stir at room temperature for half an hour. Combine the above two solutions and stir at 70°C overnight. After the reaction is cooled to room temperature, concentrate under reduced pressure, add water (30 mL) to the residue, and filter. The filter cake was washed with dichloromethane / methanol = 10 / 1 (5 mL×3) and dried to give a yellow solid 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazin-2-amine (1.2 g, yield 50%). 1H NMR (300MHz, DMSO-d6) δ8.50 (s, 1H), 7.81 (d, J = 7.2Hz, 1H), 4.42-4.31 (m, 1H), 3.98-3.94 (m, 2H), 3.4 3(t,J=7.5Hz,2H),2.92(q,J=7.2Hz,2H),1.98-1.93(m,2H),1.80-1.66(m,2H),1.31(t,J=7.2Hz,3H).

[0168] Step 10: To a mixture of 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazin-2-amine (0.960 g, 2.59 mmol) and 4-(1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)-1-tert-butyloxycarbonylpiperazine (Intermediate A, 1.30 g, 2.59 mmol) in N,N-dimethylacetamide (50 mL) was added an aqueous solution (5 mL) of sodium carbonate (824 mg, 7.78 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (190 mg, 0.26 mmol). The mixture was stirred at 100°C for 3 hours under nitrogen protection. The reaction mixture was cooled to room temperature and poured into water (150 mL). The mixed solution was extracted three times with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate to dichloromethane / methanol / 25% ammonia water = 30:1:0.1) to obtain a crude product. The crude product was purified by C18 reverse phase column chromatography (from water containing 50% acetonitrile to water containing 80% acetonitrile) to obtain yellow solid tert-butyl 4-(1-(4-(5-chloro-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridinyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-ylpiperazine-1-carboxylate (0.60 g, yield 35%). 1H NMR (300MHz, DMSO-d6) δ8.32 (s, 1H), 7.56 (d, J = 7.2Hz, 1H), 7.30-7.28 (m, 2H), 6.97-6.95 (m,1H),4.19-4.11(m,1H),3.93-3.89(m,2H),3.83(s,3H),3.52-3.49(m,2H),3.31-3.30( m,4H),3.25-3.22(m,2H),2.90(q,J=7.2Hz,2H),2.61-2.57(m,2H),2.50-2.41(m,4H),2. 38-2.32(m,1H),1.88-1.81(m,4H),1.71-1.55(m,4H),1.40(s,9H),1.32(t,J=7.2Hz,3H). MS Found:666.8[M+H] + .

[0169] Step 11: Trisdibenzylideneacetone dipalladium (21 mg, 0.024 mmol) was added to a mixture of toluene (10 mL) containing tert-butyl 4-(1-(4-(5-chloro-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridinyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-ylpiperazine-1-carboxylate (0.30 g, 0.45 mmol), (2,4-dimethoxyphenyl)methanamine (113 mg, 0.680 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (26 mg, 0.045 mmol) and sodium tert-butoxide (130 mg, 1.35 mmol). The mixture was stirred at 110° C. for 3 hours under nitrogen protection. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. , ethyl acetate (20 mL) and water (30 mL) were added to the residue. The mixed solution was extracted three times with ethyl acetate (10 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol=30:1) to obtain a crude product. The crude product was purified by C18 reverse phase chromatography (from water containing 40% acetonitrile to water containing 90% acetonitrile) to obtain yellow solid tert-butyl 4-(1-(4-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridinyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylic acid (0.13 g, yield 36%). 1H NMR(400MHz, CDCl3)δ8.16(s,1H),7.35-7.33(m,1H),7.30-7.27(m,1H),7.16(s,1H),6.96-6.94(m,2H),6.50-6.4 9(m,1H),6.46-6.43(m,1H),4.80-4.78(m,2H),4.76-4.74(m,1H),4.25-4.16(m,1H),4.01-3.98(m,2H),3.89-3.8 8(m,6H),3.80(s,3H),3.62-3.59(m,2H),3.50-3.45(m,6H),2.70(q,J=7.2Hz,2H),2.64-2.59(m,6H),2.53-2.45( m,1H),2.08-2.05(m,2H),1.89-1.82(m,4H),1.56-1.52(m,2H),1.47(s,9H),1.41(t,J=7.2Hz,3H).MS:797.5[M+H] + .

[0170] Step 12: Add tert-butyl 4-(1-(4-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-

[0171] To a solution of ((tetrahydro-2H-pyran-4-yl)amino)pyridinyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylic acid (0.13 g, 0.16 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) and stirred at 30°C for 1 hour. The reaction solution was concentrated, water (2 mL) was added to the resulting residue, and the pH value was adjusted to 10 with 5% sodium hydroxide. Extract with dichloromethane / methanol=10 / 1 six times (10 mL×6), combine the organic phases, wash with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a yellow solid 3-ethyl-8-(3-methoxy-4-(4-(piperazine-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyridine[3,4-b]pyrazine-2,5-diamine (90 mg, yield 100%). MS: 547.6[M+H] + .

[0172] Step 13: To a mixture of dichloromethane (2 mL) and methanol (1 mL) containing 3-ethyl-8-(3-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyridine[3,4-b]pyrazine-2,5-diamine (90 mg, 0.16 mmol) was added 37% aqueous formaldehyde solution (15 mg, 0.18 mmol) and 1 drop of acetic acid. After stirring at room temperature for 20 minutes, sodium cyanoborohydride (31 mg, 0.49 mmol) was added. After stirring at room temperature for 30 minutes, water (2 mL) was added and the pH value was adjusted to 10 with 5% sodium hydroxide. The mixture was extracted six times (10 mL×6) with dichloromethane / methanol = 10 / 1, and the organic phases were combined and concentrated under reduced pressure to obtain a crude product. The crude product was purified by C18 reverse phase chromatography (from water containing 10% acetonitrile to water containing 50% acetonitrile, the aqueous phase contained 0.1% hydrochloric acid) to give a yellow solid 3-ethyl-8-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyridine[3,4-b]pyrazine-2,5-diamine trihydrochloride (65 mg, yield 61%). 1 H NMR (400 MHz, DMSO-d6)δ

[0173] 13.77(s,1H),12.48-12.17(m,2H),8.54(s,2H),7.96-7.94(m,2H),7.55(br s,1H),7.43-7.32(m,2H),4.14-4.05(m,1H),3.95(s,3H),3.92-3.89(m 2H),3.79-3.60(m,12H),3.35-3.27(m,1H),3.25-3.22(m,2H),2.92-2.86(m,5H) ,2.35-2.25(m,4H),1.83-1.78(m,2H),1.74-1.64(m,2H),1.33(t,J=7.2Hz,3H). MS:561.4[M+H] + .

[0174] A similar method was used to prepare the compounds listed in the table by using other starting materials.

[0175] Referring to the synthesis method of compound 8, in step 9, tetrahydropyran-4-amine was replaced with the corresponding starting materials in the following table to prepare the compounds in the following table:

[0176]

[0177]

[0178] Referring to the synthesis method of compound 8, tetrahydropyran-4-amine was replaced with the corresponding starting materials in the table below in step 9, and the acetyl protecting group was hydrolyzed by alkaline method in the corresponding product in step 11 to prepare the compound in the table below:

[0179]

[0180] Referring to the synthesis method of compound 8, in step 3, 1-fluoro-2-methoxy-4-nitrobenzene was replaced with the corresponding starting materials in the following table to prepare the compounds in the following table:

[0181]

[0182]

[0183] Referring to the synthesis method of compound 8, the starting materials in the following table were used to replace intermediate A and react with 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazine-2-amine to prepare the corresponding compounds in the following table:

[0184] The product of step 10 in the synthesis method of compound 8 is compound 12 in the following table:

[0185]

[0186] Referring to the deprotection method of step 12 in the synthesis method of compound 8, compound 12 was used as the starting material to prepare compound 11 shown in the following table:

[0187]

[0188] Referring to the method of Example 11, compound 11 was reacted with the starting materials in the following table to obtain the following compounds:

[0189] Referring to the synthesis method of compound 8, in step 11, trimethylboroxane was used to replace (2,4-dimethoxyphenyl)methylamine and the Suzuki reaction was used to prepare the compound shown in the following table:

[0190]

[0191] Referring to the synthesis method of compound 8, in step 7, the starting materials in the following table were used to replace ethyl 2-oxobutyrate to prepare the compound in the following table:

[0192]

[0193]

[0194] Referring to the synthesis method of compound 8, in step 3, the starting materials in the following table were used to replace 4-(piperidin-4-yl)piperazine-1-carboxylic acid tert-butyl ester to prepare the compound in the following table:

[0195]

[0196] Example 2: The intermediate tert-butyl 4-(1-(4-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylic acid produced in step 11 of example 1 can also be synthesized by the following method, and then compound 8 is obtained through steps 12 and 13 of example 1.

[0197]

[0198] Step 1: A mixture of 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazine-2-amine (6.00 g, 16.1 mmol) and 2,4-dimethoxybenzylamine (15 g, 90 mmol) was stirred at 145°C overnight. The reaction was cooled to room temperature, and the mixture was purified by silica gel chromatography (petroleum ether / ethyl acetate = 5:1 to 3:1) to obtain a yellow solid 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (5.5 g, yield 68%). MS Found: 502.5 [M+H] + .

[0199] Step 2: Add cesium carbonate (5.20 g, 15.9 mmol) in water (15 mL) and Pd(dppf)Cl2 (583 mg, 0.80 mmol) to a mixture of 1,4-dioxane (100 mL) containing 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (4.00 g, 7.97 mmol) and intermediate A (4.0 g, 7.97 mmol). The mixture was stirred at 110 ° C for 3 hours under nitrogen protection. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and ethyl acetate (50 mL) and water (50 mL) were added. The mixture was extracted with ethyl acetate three times (50 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 1:1 to 0:1 and then to ethyl acetate / methanol = 20:1) to give a yellow solid intermediate B (3.1 g, yield 49%).

[0200] Referring to the method of step 9 in Example 1, tetrahydropyran-4-amine was replaced with the corresponding starting materials in the table below for reaction, and then the synthesis method of compound 8 indicated in Example 2 was reacted with intermediate M to prepare the compounds shown in the following table:

[0201]

[0202] Referring to the synthesis method of compound 8 in Example 1, tetrahydropyran-4-amine was replaced with the corresponding starting materials in the table below in step 9, and then referring to the method of Example 2, the compounds shown in the following table were prepared:

[0203]

[0204] Using methylamine instead of 2,4-dimethoxybenzylamine as the starting material, the following compound 10 was obtained by referring to the synthesis method of Example 2.

[0205]

[0206] Substituting the starting materials in the following table for 1-fluoro-2-methoxy-4-nitrobenzene, the following compound 23 was obtained by referring to the synthesis method of intermediate A in Example 1 and the synthesis method of Example 2.

[0207]

[0208] Using 1-fluoro-2-methyl-4-nitrobenzene and tert-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate in the following table to replace 1-fluoro-2-methoxy-4-nitrobenzene and tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate, respectively, refer to the synthesis method of intermediate A in Example 1 and the synthesis method of Example 2 to obtain the following compound 31.

[0209]

[0210] Substituting the starting materials in the following table for tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate, the following compounds were obtained by referring to the synthesis methods of intermediate A in Example 1 and Example 2.

[0211]

[0212] Substituting the starting materials in the following table for 1-benzyl-4-piperidone, the following compounds were obtained by referring to the synthesis method of intermediate A in Example 1 and the synthesis method of Example 2.

[0213]

[0214] Referring to the synthesis method of Example 1, in step 7, ethyl 2-oxobutyrate was replaced with the starting material in the following table, and then referring to the synthesis method of Example 2, the compound in the following table was obtained:

[0215]

[0216] Substituting the starting materials in the following table for tert-butyl 4-(4-(4-iodo-2-methoxyphenyl)cyclohexyl)piperazine-1-carboxylate, the following compounds were obtained by referring to the synthesis methods of intermediate A in Example 1 and Example 2.

[0217]

[0218] Example 3: 3-ethyl-8-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)-N 2-tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 21)

[0219]

[0220] Step 1: Dissolve 5-bromo-2-fluoropyridine (500 mg, 2.84 mmol) and 1-methyl-4-(4-piperidinyl)piperazine (520 mg, 2.84 mmol) in N,N-dimethylformamide (10 mL), and add potassium carbonate (784 mg, 5.68 mmol). The mixture was stirred at 110 ° C for 6 hours. The reaction was cooled to room temperature, water (40 mL) was added, and ethyl acetate was extracted (20 mL × 3), and the organic phases were combined. The organic phase was washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane: methanol = 20: 1 to 10: 1) to obtain a white solid (800 mg, yield 83%). 1 HNMR (400MHz, CDCl3): δ8.16(d,J=2.0Hz,1H),7.49(dd,J=8.8,2.0Hz,1H),6.56(d,J=8.8Hz,1H),4.29-4.26(m, 2H),2.86-2.79(m,2H),2.71-2.55(m,4H),2.49-2.42(m,5H),2.28(s,3H),1.93-1.85(m,2H),1.57-1.47(m,2H).

[0221] Step 2: Add potassium acetate (364 mg, 3.19 mmol) and Pd(dppf)Cl2 (117 mg, 0.16 mmol) to a mixture of N,N-dimethylformamide (5 mL) containing 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (800 mg, 1.59 mmol) and bisvaleryl diboron (810 mg, 3.19 mmol). The mixture was stirred at 110°C for 5 hours under nitrogen protection. The reaction was cooled to room temperature and water (30 mL) was added. The mixed solution was extracted three times with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 1:1 to 0:1 and then to ethyl acetate / methanol = 10:1) to obtain brown solid intermediate C (230 mg, yield 31%). MSFound: 468.6 [M+H] + .

[0222] Step 3: Referring to the method of step 2 of Example 2, 1-(1-(5-bromopyridin-2-yl)piperidin-4-yl)-4-methylpiperazine (87 mg, 0.26 mmol) and intermediate C (100 mg, 0.21 mmol) were reacted to obtain yellow solid N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)-N2-(tetrahydro-2H)pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (70 mg, yield 49%). MS Found: 682.6[M+H] + .

[0223] Step 4: Referring to the method of Step 12 of Example 1, N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)-N2-(tetrahydro-2H)pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (70 mg, 0.1 mmol) was reacted to obtain yellow solid Compound 21 (70 mg, 0.1 mmol). 1 H NMR (400MHz, DMSO-d6): δ8.38(d,J=2.0Hz,1H),7.92-7.88(m,2H),7.05(d,J=6.8Hz ,1H),6.85(d,J=8.8Hz,1H),6.45(s,2H),4.35-4.31(m,2H),4.11-4.03(m,1H),3.9 3-3.91(m,2H),3.40-3.28(m,4H),2.83-2.78(m,4H),2.42-2.30(m,7H),2.14(s,3H ),1.89-1.80(m4H),1.66-1.57(m,2H),1.44-1.34(m,2H),1.31(t,J=7.2Hz,3H).MS Found:532.3[M+H] + .

[0224] Example 4: 3-ethyl-8-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(methylsulfonyl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 18)

[0225]

[0226] Step 1: Dissolve commercially available 1-chloro-2-(methylsulfonyl)-4-nitrobenzene (1.20 g, 5.08 mmol) and 1-methyl-4-(4-piperidinyl)piperazine (931 mg, 5.08 mmol) in dimethyl sulfoxide (20 mL), and add potassium carbonate (1.40 g, 10.2 mmol). The mixture was stirred at 100°C for 2 hours. The reaction mixture was cooled to room temperature, added to water (100 mL), extracted with ethyl acetate (20 mL×5), and the organic phases were combined. The organic phase was washed with saturated brine (10 mL×2) and concentrated under reduced pressure. Dichloromethane (20 mL) was added, poured into a concentrated hydrochloric acid (3 mL) aqueous solution (30 mL), and washed with dichloromethane (20 mL). The aqueous phase was alkalized to pH with 5% sodium hydroxide solution and extracted with dichloromethane (20 mL×4). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a brown solid (1.70 g, yield 87%). [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.95(d,J=2.8Hz,1H),8.42(dd,J=8.8,2.8Hz,1H),7.44(d,J=9.2Hz,1H),3.55-3.52(m,2H),3.32(s,3H),2 .87-2.81(m,2H),2.73-2.65(m,4H),2.58-2.50(m,4H),2.43-2.34(m,1H),2.30(s,1H),2.08-2.05(m,2H),1.82-1.72(m,2H).MS Found:383.2.

[0227] Step 2: Referring to the method of step 4 of Example 1, 1-methyl-4-(1-(2-(methylsulfonyl)-4-nitrophenyl)piperidin-4-yl)piperazine was used as the starting material to obtain white solid 4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(methylsulfonyl)aniline (1.50 g, yield 96%). MS Found: 353.5 [M+H] + .

[0228] Step 3: 4-(4-(4-methylpiperazine-1-yl)piperidin-1-yl)-3-(methylsulfonyl)aniline (600 mg, 1.70 mmol) was dissolved in an aqueous solution (5 mL) of concentrated sulfuric acid (834 mg, 8.51 mmol). The temperature was lowered to 0°C, and an aqueous solution (0.5 mL) of sodium nitrite (117 mg, 8.51 mmol) was added dropwise, and stirred at 0-5°C for 10 minutes. Then, an aqueous solution (2 mL) of potassium iodide (565 mg, 3.40 mmol) was added dropwise, and stirred at 5°C for 30 minutes. Poured into water (5 mL), alkalized to pH 10 with 5% sodium hydroxide solution, and extracted with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 10:1) and then by C18 column (40-80% acetonitrile in water) to give a yellow solid (250 mg, yield 32%). MS Found: 464.1 [M+H] + .

[0229] Steps 4 and 5: According to the method of steps 3 and 4 of reference example 3, 1-(1-(4-iodo-2-(methylsulfonyl)phenyl)piperidin-4-yl)-4-methylpiperazine (87 mg, 0.26 mmol) and intermediate C (200 mg, 0.43 mmol) were reacted to obtain yellow solid compound 18 (60 mg, two-step yield 46%). 1 H NMR (400MHz, DMSO-d6) δ8.46(d,J=1.2Hz,1H),7.98(s,1H),7.91(d,J=8.4Hz,1H),7.55(d,J=8.4Hz ,1H),7.06(d,J=7.6Hz,1H),6.62(s,2H),4.28-4.18(m,1H),3.84-3.82(m,2H),3.40(s,3H),3.38-

[0230] 3.32(m,4H),3.26-3.23(m,2H),2.84-2.77(m,5H),2.73-2.59(m,6H),2.37(s,3H),1.93-

[0231] 1.91(m,2H),1.82-1.79(m,2H),1.64-1.57(m,4H),1.31(t,J=7.2Hz,3H).MSFound:609.4[M+H] + .

[0232] Example 5: 2-(5-(5-amino-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4-b]pyrazin-8-yl)-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)propan-2-ol (Compound 19)

[0233]

[0234] Step 1: The method of step 1 of reference example 4 was used to react 1-(5-bromo-2-fluorophenyl)ethanone (1.20 g, 5.53 mmol) and 1-methyl-4-(4-piperidinyl)piperazine (1.01 g, 5.53 mmol) to obtain a yellow solid (1.40 g, yield 67%). MSFound: 380.1[M+H] + .

[0235] Step 2: Add methylmagnesium bromide solution in tetrahydrofuran (3.0M, 1.05mL, 3.16mmol) dropwise to a tetrahydrofuran solution (10mL) of 1-(5-bromo-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)ethan-1-one (400mg, 1.05mmol) at 0°C under nitrogen protection. Stir for 1 hour at 0-5°C, pour into water (10mL), extract with dichloromethane / methanol (10 / 1, 10mL×3), combine the organic phases, and concentrate under reduced pressure. The residue was purified by C18 column (10-60% acetonitrile in water) to obtain a white solid (170mg, yield 41%).

[0236] Steps 3 and 4: Using the method of steps 3 and 4 of Example 3, 2-(5-bromo-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)propan-2-ol (102 mg, 0.26 mmol) and intermediate C (120 mg, 0.26 mmol) were reacted to obtain white solid compound 19 (60 mg, two-step yield 30%). 1H NMR (400MHz, DMSO-d6): δ7.92(s.1H),7.64-7.61(m,2H),7.54(br,1H),7.39(d,J=8.0Hz,1H),7.01(d,J=7.2Hz,1H),6.52(s,2H),4.20-4 .12(m,1H),3.90-3.88(m,2H),3.30-3.27(m,4H),2.97-2.88(m,4H),2.81(q,J=7.2Hz,2H),2.74-2.59(m,7H),2.37(s,3H),1.95-1.92(m 2H),1.84-1.80(m,2H),1.67-1.58(m,2H),1.57-1.48(m,8H),1.31(t,J=7.2Hz,3H).MS Found:589.4[M+H] + .

[0237] Example 6: 3-ethyl-8-(3-((4-(4-methylpiperazin-1-yl)piperidin-1-yl)methyl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 43)

[0238]

[0239] Step 1: Referring to the method of Step 2 of Example 2, 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (150 mg, 0.3 mmol) and 3-formylphenylboronic acid (54 mg, 0.36 mmol) were reacted to obtain a yellow solid intermediate B (110 mg, yield 69%).

[0240] Step 2: Add 1 drop of acetic acid to a mixture of 3-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4-b]pyrazin-8-yl)benzaldehyde (110 mg, 0.21 mmol) and 1-methyl-4-(piperidin-4-yl)piperazine (57 mg, 0.31 mmol) in dichloromethane (5 mL). After stirring at room temperature for 5 hours, sodium triacetoxyborohydride (133 mg, 0.63 mmol) was added. After stirring at room temperature overnight, water (5 mL) was added. The mixture was extracted with dichloromethane (15 mL×4), the organic phases were combined, the organic phases were washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 30:1 to 15:1) to obtain a yellow solid (100 mg, yield 69%). MS Found: 695.7 [M+H] + .

[0241] Step 3: Referring to the deprotection method of step 12 in the synthesis method of compound 8, N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(3-((4-(4-methylpiperazin-1-yl)piperidin-1-yl)methyl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (80 mg, 0.12 mmol) was used as the starting material to prepare white solid compound 43 (40 mg, yield 61%). 1 H NMR(400MHz, DMSO-d6)δ8.01(s.1H),7.76-7.71(m,2H),7.42-7.38(m,2H),7.16(d,J=7.2Hz,2H),6.75(s,2H),4.13-4.04(m,1H),3.93-3.90 (m,3H),3.32-3.26(m,5H),3.15-3.06(m,3H),2.93-2.72(m,10H),2.5 4(s,3H),1.86-1.84(m4H),1.70-1.61(m,4H),1.31(t,J=7.2Hz,3H).MS Found:545.3[M+H] + .

[0242] Example 7: 3-ethyl-8-(3-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 45)

[0243]

[0244] Step 1: Add cesium acetate (5.0 g, 15 mmol) and Pd2(dba)3 (0.50 g, 0.50 mmol) and BINAP (0.60 g, 1.0 mmol) to a mixture of 1,4-dioxane (15 mL) containing 1-methyl-4-(piperidin-4-ylmethyl)piperazine (1.0 g, 5.1 mmol) and 1-bromo-4-chloro-2-methoxybenzene (1.1 g, 5.1 mmol). The mixture was stirred at 110 ° C for 3 hours under nitrogen protection. The reaction was cooled to room temperature and water (30 mL) was added. The mixed solution was extracted three times with ethyl acetate (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 4:1) to obtain a yellow oil (620 mg, yield 35%). (ESI) m / z 338.1.[M+H] + .

[0245] Step 2: Potassium acetate (291 mg, 3.6 mmol), Pd(dba)2 (14 mg, 0.020 mmol) and X-Phos (11 mg, 0.020 mmol) were added to a mixture of 1,4-dioxane (10 mL) containing 1-((1-(4-chloro-2-methoxyphenyl)piperidin-4-yl)methyl)-4-methylpiperazine (400 mg, 1.2 mmol) and bisvaleryl diboron (601 mg, 2.4 mmol). The mixture was stirred at 110 ° C for 16 hours under nitrogen protection. The reaction mixture was cooled to room temperature, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 4:1) to give a yellow oil (400 mg, yield 75%). (ESI) m / z 430.2. [M+H] + .

[0246] Step 3: Referring to the method of step 2 of Example 2, 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine (137 mg, 0.31 mmol) and 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (100 mg, 0.21 mmol) were reacted to give a yellow oil (112 mg, yield 79%). (ESI) m / z 725.3.[M+H] + .

[0247] Step 4: Dissolve N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(3-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (112 mg, 0.16 mmol) in a methanol solution of hydrochloric acid (4M, 5 mL) and stir at 25 °C for 16 hours. The reaction was cooled to room temperature and quenched with saturated sodium bicarbonate solution (10 mL). The mixed solution was extracted three times with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to give the formate salt of yellow solid compound 45 (19 mg, yield 20%). 1 H NMR(400MHz,DMSO-d6)δ8.25(s,1H),7.92(s,1H),7.24–7.17(m,2H),7.00(d,J=7.2Hz,1H),6.89 (d,J=8.0Hz,1H),6.44(s,2H),4.14–4.10(m,1H),3.90(d,J=8.4Hz,2H),3.81(s,3H),3.24(s,6H) ,2.83-2.78(m,2H),2.54(d,J=12.8Hz,3H),2.43–2.22(m,5H),2.17(d,J=7.2Hz,2H),2.15(s,3H ),1.86(d,J=12.4Hz,2H),1.77(d,J=12.0Hz,2H),1.68–1.56(m,3H),1.33–1.22(m,5H).(ESI)m / z 575.3.[M+H] + .

[0248] Referring to the method of step 1 in Example 7, the starting materials in the following table were used to replace 1-bromo-4-chloro-2-methoxybenzene to prepare the corresponding intermediate, and then 1-methyl-4-(4-piperidinyl)piperazine was used to replace 1-methyl-4-(piperidin-4-ylmethyl)piperazine, and the following compound was obtained according to the method of Example 7:

[0249]

[0250] Referring to the method of step 9 in Example 1 and the method of step 1 in Example 2, the starting materials in the following table were used instead of tetrahydropyran-4-amine to prepare the corresponding intermediates, and then referring to the method of Example 7, 1-methyl-4-(4-piperidinyl)piperazine was used instead of 1-methyl-4-(piperidin-4-ylmethyl)piperazine to prepare the following compounds:

[0251]

[0252]

[0253]

[0254] Substituting the starting materials in the following table for 1-methyl-4-(piperidin-4-ylmethyl)piperazine, the following compound was obtained by referring to the method of Example 7:

[0255]

[0256] The starting materials in the following table were used to replace 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine, and the method of Example 7 and the catalytic hydrogenation method of Step 4 of Example 1 were used to obtain the compounds in the following table.

[0257]

[0258]

[0259] Substitute the starting materials in the following table for 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine, and remove the protecting group by referring to the method of step 2 in Example 2 and then referring to the method of step 12 in Example 1 to obtain the compounds in the following table:

[0260]

[0261] The starting materials in the following table were used to replace 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine, and the method of Example 7 was followed to obtain the compounds in the following table.

[0262]

[0263] Referring to the method of step 9 in Example 1, the starting material 2 in the following table was used to replace tetrahydropyran-4-amine to prepare the corresponding intermediate, and then the starting material 1 was used to replace 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine, and the method starting from step 3 in Example 7 was used to obtain the following compound

[0264]

[0265] Example 8: 3-ethyl-8-(4-methylpiperazin-1-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-

[0266] 2,5-Diamine (Compound 53)

[0267]

[0268] Step 1: To a mixture of 1,4-dioxane (5 mL) containing 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (75 mg, 0.15 mmol) and 1-methylpiperazine (30 mg, 0.30 mmol), potassium tert-butoxide (43 mg, 0.45 mmol) and tBuXPhos Pd G3 (27 mg, 0.030 mol), tBuXPhos (28 mg, 0.060 mmol) were added. The mixture was stirred at 110°C for 14 hours under nitrogen protection. The reaction was cooled to room temperature and water (10 mL) was added. The mixed solution was extracted three times with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 10:1) to obtain a brown oil (50 mg, yield 64%). (ESI) m / z 522.2.[M+1] + .

[0269] Step 2: Referring to the method of Step 4 of Example 7, use N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(4-methylpiperazin-1-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (50 mg, 0.096 mmol) to prepare yellow solid Compound 53 (15 mg, 42%). 1 H NMR(400MHz, DMSO-d6)δ8.18(brs,2H),7.37(s,1H),7.05(d,J=7.2Hz,1H),6.16(brs,2H),4.25–4.19(m,1H),3.98–3.94(m,2H),3.41–3.35(m,2H ),3.22–3.06(m,2H),2.79(d,J=7.2Hz,2H),2.59–2.52(m,4H),2.28(s,3 H),1.93–1.87(m,2H),1.72–1.62(m,2H),1.28(t,J=7.2Hz,4H).(ESI)m / z

[0270] 373.1.[M+1] + .

[0271] Example 9: 3-((5-amino-3-ethyl-8-(1-(1'-methyl-[1,4'-bipiperidinyl]-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentane-1-ol (Compound 134)

[0272] Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with compound 206 to obtain the following compound:

[0273]

[0274] Example 10: Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with compound 58 to obtain the following compound

[0275]

[0276]

[0277]

[0278] Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with compound 58, and then the protecting group was removed according to the method of step 4 in Example 7 to obtain the following compound:

[0279]

[0280] The starting materials in the following table were reacted with compound 58 according to the method of step 2 in Example 6, and then the protecting group was removed according to the method of step 12 in Example 1. Finally, the compound 6 was reacted with formaldehyde according to the method of step 2 to obtain the compound in the following table:

[0281]

[0282] Referring to the method of step 2 in Example 6, paraformaldehyde and compound 157 were reacted to obtain the following compound:

[0283]

[0284] Example 11: 3-ethyl-8-(1-(1-(pentan-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 232)

[0285]

[0286] 3-Bromopentane (360 mg, 2.4 mmol) and diisopropylethylamine (90 mg, 0.70 mmol) were added to a solution of compound 58 (100 mg, 0.20 mmol) in acetonitrile (3 mL). The mixture was stirred at 105 ° C in a sealed tube for 16 hours. The reaction was cooled to room temperature and water (10 mL) was added. The mixed solution was extracted with ethyl acetate three times (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to obtain the formate salt of yellow solid compound 232 (30 mg, yield 23%). 1 H NMR(400MHz,DMSO-d6)δ8.34(s,1H),8.17(brs,4H),8.01(s,1H),7.05(d,J=8.0Hz,1H),6 .44(brs,2H),4.35–4.26(m,1H),4.17–4.09(m,1H),4.01–3.94(m,2H),3.49–3.43(m,2H), 2.83–2.82(m,4H),2.46(d,J=12.0Hz,2H),2.30–2.23(m,1H),2.06(d,J=8.0Hz,2H),1.99 –1.88(m,4H),1.74–1.70(m,2H),1.52–1.45(m,2H),1.37–1.24(m,5H),0.91–0.87(m,6H).

[0287] (ESI)m / z.493.2[M+1] + .

[0288] Example 12: 3-ethyl-8-(5-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-2-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 20)

[0289]

[0290] Step 1: Add tridibenzylideneacetone dipalladium (447 mg, 0.49 mmol) to a toluene mixture (20 mL) containing 3-iodopyridine (1.00 g, 4.88 mmol), 1-methyl-4-(4-piperidinyl)piperazine (893 mg, 4.88 mmol), Xantphos (282 mg, 0.49 mmol) and potassium tert-butoxide (1.09 g, 9.76 mmol). The mixture was stirred at 108 ° C for 4 hours under nitrogen protection. The reaction was cooled to room temperature, and dichloromethane (20 mL) and water (20 mL) were added. The mixed solution was extracted three times with dichloromethane (20 mL×3). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was passed through a silica gel chromatography column (dichloromethane / methanol

[0291] =10:1 to dichloromethane / methanol / 25% aqueous ammonia solution = 10:1:0.1) to give a yellow solid (750 mg, yield 59%). 1 H NMR (400MHz, CDCl3) δ8.30 (d, J = 2.8Hz, 1H), 8.07-8.05 (m, 1H), 7.20-7.17 (m, 1H), 7.15-7.12 (m, 1H), 3.77-3.74 (m, 2H), 2.81- 2.74(m,2H),2.65-2.60(m,4H),2.51-2.44(m,2H),2.41-2.38(m,1H),2.31(s,3H),2.19-2.06(m,2H),1.98-1.95(m,2H),1.72-

[0292] 1.62(m,2H).

[0293] Step 2: Add NBS (770 mg, 4.33 mmol) in a dichloromethane mixture (30 mL) containing 1-methyl-4-(1-(pyridin-3-yl)piperidin-4-yl)piperazine (750 mg, 2.88 mmol) in batches under ice bath conditions. Stir the reaction at 5-20°C for 2 hours, then pour into water (20 mL). The mixed solution is extracted with dichloromethane (20 mL×4). The organic phases are combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel chromatography (dichloromethane / methanol = 20:1 to 10:1) to obtain a yellow solid (500 mg, yield 51%). 1H NMR (400MHz, CDCl3) δ8.00 (d, J=3.2Hz, 1H), 7.28-7.16 (m, 1H), 7.07 (dd, J=8.8, 3.2Hz, 1H), 3.71-3.6 8(m,2H),2.80-2.74(m,2H),2.63-2.36(m,9H),2.30(s,3H),1.97-1.94(m,2H),1.69-1.59(m,2H).MS Found:339.1[M+H] + .

[0294] Steps 3 and 4: According to the method of steps 3 and 4 of reference example 3, 1-(1-(6-bromopyridin-3-yl)piperidin-4-yl)-4-methylpiperazine (145 mg, 0.43 mmol) and intermediate C (200 mg, 0.43 mmol) were reacted to give yellow solid compound 20 (60 mg, two-step yield 26%). 1 H NMR(400MHz,DMSO-d6)δ8.46(s,1H),8.35-8.31(m,2H),7.39-7.36(m,1H),7.24-7.22(m,1H),6.82(s,2H),4.22-4.14(m,1H),3.96-3.94(m ,2H),3.88-3.85(m,2H),3.46-3.40(m,3H),3.07-2.73(m,12H),2.58( s,3H),1.94-1.91(m,4H),1.72-1.58(m,4H),1.32(t,J=7.2Hz,3H).MS Found:532.2[M+H] + .

[0295] Example 13: (1S,3R)-3-((5-amino-8-bromo-3-ethylpyrido[3,4-b]pyrazin-2-yl)amino)cyclopentane-1-ol (Compound 151)

[0296]

[0297] Steps 1 and 2, synthesis of intermediate D: Referring to the method of step 9 of Example 1 and step 1 of Example 2, (1S, 3R)-3-aminocyclopentanol hydrochloride was used to prepare yellow solid intermediate D (two-step yield 40%). 1H NMR(400MHz,DMSO-d6)δ8.01(s,1H),7.31–7.17(m,2H),7.07(d,J=8.0Hz,1H),6 .56(s,1H),6.44–6.38(m,1H),5.76(s,1H),4.74(d,J=3.6Hz,1H),4.56(d,J=6.0 Hz,2H),4.52–4.41(m,1H),3.83(s,3H),3.72(s,3H),2.83–2.77(m,2H),2.13–1. 99(m,2H),1.83–1.72(m,2H),1.68–1.56(m,2H),1.30(t,J=7.2Hz,3H).(ESI)m / z 502.0[M+H] + .

[0298] Step 3: According to the method of step 12 of Example 1, yellow solid compound 151 (56 mg, yield 79%) was obtained from intermediate D (100 mg, 0.20 mmol). 1 H NMR (400MHz, DMSO-d6) δ8.14(brs,1H),8.00(s,1H),7.43(d,J=6.8Hz,1H),6.98(brs,2H),4.76(s,1H),4.55–4.45(m,1H),4.22–

[0299] 4.13(m,1H),2.81(q,J=7.2Hz,2H),2.36–2.27(m,1H),2.12–2.01(m,1H ),1.87–1.73(m,2H),1.70–1.58(m,2H),1.30(t,J=7.2Hz,3H).(ESI)m / z 352.1.[M+H] + .

[0300] Example 14: Referring to the method of step 2 of Example 2, the starting materials in the following table were reacted with compound 151 to obtain the corresponding compound

[0301]

[0302]

[0303]

[0304] Example 15: (1S, 3R)-3-((5-amino-3-ethyl-8-(1-(piperidin-4-yl)-1H-pyrrol-3-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 152) and (1S, 3R)-3-((5-amino-3-ethyl-8-(1-(1-methylpiperidin-4-yl)-1H-pyrrol-3-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 153)

[0305]

[0306] Referring to the method of Example 3, intermediate E was prepared from intermediate D, and the obtained product was reacted with tert-butyl 4-(3-bromo-1H-pyrrol-1-yl)piperidine-1-carboxylate. The obtained product was deprotected according to the method of step 12 of Example 1 to obtain yellow solid compound 152. Compound 152 was reacted with formaldehyde according to the method of step 2 of Example 6 to obtain yellow solid compound 153.

[0307] Compound 152: 1 H NMR(400MHz,DMSO-d6)δ7.68(s,1H),6.96(d,J=7.2Hz,1H),6.88(s,1H),6.49(s,2H ),6.07(t,J=4.0Hz,1H),5.87(s,1H),4.77(d,J=3.6Hz,1H),4.31(d,J=6.4Hz,1H), 4.09(s,1H),3.80(s,1H),2.92(d,J=12.0Hz,2H),2.77–2.72(m,2H),2.24(s,1H),2 .00-1.90(m,1H),1.81–1.47(m,11H),1.29(t,J=7.2Hz,3H).(ESI)m / z.422.2[M+1] + .

[0308] Compound 153: 1H NMR(400MHz,DMSO-d6)δ7.69(s,1H),7.00(d,J=7.2Hz,1H),6.90(s,1H),6.55(s,2H ),6.10(t,J=4.0Hz,1H),5.90-5.89(m,1H),4.79(d,J=3.6Hz,1H),4.37–4.24(m,1H ),4.09(d,J=4.0Hz,1H),3.80(s,1H),2.95(s,2H),2.77–2.72(m,2H),2.30(s,3H), 2.02–1.57(m,11H),1.55–1.49(m,1H),1.30(t,J=7.2Hz,3H).(ESI)m / z.436.2[M+1] + .

[0309] Example 16: Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with compound 154 to obtain the following compound

[0310]

[0311] Example 17: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentane-1-ol (Compound 169)

[0312]

[0313] Step 1: Add triethylamine (8.9 g, 88 mmol) and methanesulfonyl chloride (2.4 g, 21 mmol) to a dichloromethane solution (30 mL) containing 4-hydroxy-1,2,2,6,6-pentamethylpiperidine (3 g, 18 mmol) at 0°C. Stir the reaction at 25°C for 6 hours. After the reaction, quench with saturated sodium bicarbonate solution. Extract the mixture twice with dichloromethane (30 mL

[0314] ×2). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow oil (74.2 g, yield 96%), which was directly used in the next step. (ESI) m / z 250.2.[M+H]+.

[0315] Step 2: Add sodium hydride (0.48 g, 12 mmol) to a solution of 4-pyrazole boric acid naphthalene ester (2.3 g, 12 mmol) in N, N-dimethylformamide (20 mL). After stirring at 25 ° C for 1 hour, add the product of step 1 (1,2,2,6,6-pentamethylpiperidin-4-yl) methanesulfonate (2.0 g, 8.0 mol), and stir at 110 ° C for 12 hours. After cooling to room temperature, the mixed solution was extracted with ethyl acetate (30 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to obtain a yellow oil (23 mg, 1.3%) (ESI) m / z.348.2 [M+H] + .

[0316] Steps 3 and 4: Referring to the method of step 2 in Example 2 and then to the method of removing the protecting group in step 12 in Example 1, intermediate D (15 mg, 0.03 mmol) was reacted with the product of step 2 (26 mg, 0.075 mmol) to obtain yellow solid compound 169 (4.5 mg, two-step yield 28%). 1 H NMR (400MHz, DMSO-d6) δ8.44(s,1H),8.20(d,J=8.0Hz,4H),8.02(s,1H),7.10(d,J=8 .0Hz,1H),6.38(s,2H),4.54–4.49(m,2H),4.25–4.20(m,1H),2.81–2.78(m,2H),2.33 –2.29(m,1H),2.25(s,3H),2.09–2.05(m,1H),2.00–1.97(m,2H),1.89–1.80(m,5H),1 .71–1.61(m,2H),1.32–1.29(m,3H),1.16(s,6H),1.11(s,6H).(ESI)m / z.493.3[M+H] + .

[0317] Referring to the method starting from step 3 in Example 17, the starting materials in the following table were reacted with intermediate D, and then reacted with iodomethane according to the method of Example 11 to obtain the following compound:

[0318]

[0319] Referring to the method starting from step 3 in Example 17, the starting materials shown in the following table were reacted to obtain the corresponding compounds:

[0320]

[0321] Referring to the method starting from step 2 in Example 17, the corresponding compounds were obtained by reacting the starting materials shown in the following table:

[0322]

[0323]

[0324] Referring to the method of Example 17, the starting materials shown in the following table were used instead of 4-hydroxy-1,2,2,6,6-pentamethylpiperidine to carry out the reaction to obtain the corresponding compound:

[0325]

[0326]

[0327] Embodiment 18:

[0328]

[0329] Step 1: Referring to the method of step 2 of Example 2, intermediate D (0.30 g, 0.60 mmol) was used as the starting material and reacted with tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (0.45 g, 1.2 mmol) to obtain a yellow solid (180 mg, yield 45%). (ESI) m / z 673.3.[M+H] + .

[0330] Step 2: Referring to the method of step 12 in Example 1, the product of step 1 (0.18 g, 0.27 mmol) was used as the starting material to obtain yellow solid intermediate F (80 mg, yield 71%). (ESI) m / z 423.3.[M+H] + .

[0331] Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with intermediate F, and then the protecting group was removed by referring to the method of step 12 in Example 1. Finally, the compound in the following table was reacted with paraformaldehyde by referring to the method of step 2 in Example 6.

[0332]

[0333] Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with intermediate F to obtain the following compounds:

[0334]

[0335]

[0336] Referring to the method of Example 11, the starting materials in the following table and intermediate F were reacted to obtain the corresponding compounds in the following table:

[0337]

[0338]

[0339]

[0340] Referring to the method of step 3 of Example 35, the starting materials in the following table and intermediate F were reacted to obtain the corresponding compounds in the following table:

[0341]

[0342] Example 19: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentane-1-ol (Compound 181)

[0343]

[0344] A solution of intermediate F (90 mg, 0.21 mmol) and 2,2-dimethyloxirane (46 mg, 0.64 mmol) in ethanol (10 mL) was stirred at 80 ° C for 12 hours. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 70%:30%) to give a yellow solid compound 181 (65 mg, yield 59%). 1 HNMR (400MHz, DMSO-d6) δ8.44(s,1H),8.20(s,1H),8.02(s,1H),7.11(d,J=7.2Hz,1H),6.37(brs,2H),4.79(d,J=3.6Hz,1H) ,4.54–4.44(m,1H),4.28–4.20(m,1H),4.17–4.05(m,2H),3.11–2.99(m,2H),2.80(q,J=7.2Hz,2H),2.38–2.21(m,5H),2.12–

[0345] 1.77(m,7H),1.75–1.60(m,2H),1.31(t,J=7.2Hz,3H),1.11(s,6H).(ESI)m / z.495.2

[0346] [M+1] + .

[0347] Referring to the method of Example 19, the starting materials shown in the following table were used to react to obtain the corresponding compounds shown in the following table:

[0348]

[0349] Example 20: 4-(4-(5-amino-3-ethyl-2-(((1R,3S)-3-hydroxycyclopentyl)amino)pyrido[3,4-b]pyrazin-8-yl)-1H-pyrazol-1-yl)-N-isopropylpiperazine-1-carboxamide (Compound 189)

[0350]

[0351] Isopropyl isocyanate (19 mg, 0.23 mmol) was added to a solution of intermediate F (80 mg, 0.19 mmol) and triethylamine (57 mg, 0.57 mmol) in tetrahydrofuran (10 mL). The mixture was stirred at 25 ° C for 2 hours and concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 70%: 30%) to give yellow solid compound 189 (38 mg, yield 37%). 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.17(s,1H),8.05(s,1H),7.13(d,J=6.9Hz,1H),6.47(brs,2 H),6.24(d,J=7.6Hz,1H),4.79(d,J=3.6Hz,1H),4.51–4.42(m,1H),4.38–4.28(m,1H),4.25–4.18( m,1H),4.14–4.06(m,2H),3.77(dd,J=13.4,6.8Hz,1H),2.89–2.73(m,4H),2.27(dd,J=13.4,6.8Hz ,1H),2.10–1.98(m,3H),1.89–1.61(m,7H),1.30(t,J=7.2Hz,3H),1.07(d,J=6.8Hz,6H).(ESI)m / z 508.3.[M+1] + .

[0352] Example 21: 1-(4-(4-(5-amino-3-ethyl-2-(((1R,3S)-3-hydroxycyclopentyl)amino)pyrido[3,4-b]pyrazin-8-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 185)

[0353]

[0354] A solution of isobutyric acid (25 mg, 0.28 mmol), EDCI (109 mg, 0.57 mmol), HOBT (77 mg, 0.57 mmol) and diisopropylethylamine (147 mg, 1.1 mmol) in N, N-dimethylformamide (5 mL) was stirred at 0°C for half an hour, and then intermediate F (80 mg, 0.19 mmol) was added. The mixture was stirred at 25°C for 2 hours, and water (20 mL) was added after the reaction was completed. The mixed solution was extracted three times with ethyl acetate (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol

[0355] =95%:5%) was purified to give a yellow solid compound (50 mg, yield 51%). 1 H NMR (400MHz, DMSO-d6) δ8.40(s,1H),8.19(s,1H),8.06(s,1H),7.08(d,J=7.2Hz,1H),6.37( brs,2H),4.79(d,J=3.6Hz,1H),4.56–4.40(m,3H),4.25–4.17(m,1H),4.12–4.02(m,1H),3.2 7–3.18(m,1H),2.96–2.89(m,1H),2.80(q,J=7.2Hz,2H),2.53–2.52(m,1H),2.31–2.22(m,1 H),2.17–2.00(m,3H),1.88–1.63(m,6H),1.30(t,J=7.2Hz,3H),1.06–0.99(m,6H).(ESI)m / z 493.3.[M+1] + .

[0356] Example 22: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(6-methylpyridin-3-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 177)

[0357]

[0358] Step 1: Add 4-bromopyrazole (1.0 g, 6.8 mmol), cesium carbonate (6.6 g, 21 mmol), cuprous iodide (0.13 g, 0.60 mmol) and trans-N,N-dimethylcyclohexane-1,2-diamine (0.19 g, 1.3 mmol) to a solution of 2-methyl-5-bromopyridine (2.3 g, 14 mmol) in N,N-dimethylformamide (20 mL). The mixture was stirred at 110 ° C for 12 hours under nitrogen protection. The reaction mixture was cooled to room temperature and water (50 mL) was added. The mixed solution was extracted with ethyl acetate three times (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 70%: 30%) to obtain a yellow oil (900 mg, yield 29%). (ESI) m / z.238.1 [M+H] + .

[0359] Steps 2 and 3: Referring to the methods of step 6 of Example 1 and step 2 of Example 2, respectively, 5-(4-bromo-1H-pyrazol-1-yl)-2-methylpyridine was used as the starting material to obtain the borate intermediate, which was then reacted with compound 151 to obtain yellow solid compound 177 (two-step yield 11%). 1 H NMR(400MHz, DMSO-d6)δ9.07(s,1H),8.94(d,J=2.8Hz,1H),8.46(s,1H),8.30(s,1H),8.12–8.09(m ,1H),7.42(d,J=8.4Hz,1H),7.23(d,J=6.8Hz,1H),6.66(s,2H),4.82(d,J=3.6Hz,1H),4.59–4.51(m ,1H),4.24–4.18(m,1H),2.85–2.79(m,2H),2.52(s,3H),2.32–2.27(m,1H),2.11–2.03(m,1H),1.91 –1.76(m,2H),1.71–1.64(m,2H),1.32(t,J=7.2Hz,3H).LC-MS:Rt=1.051min,(ESI)m / z.431.2[M+1] + .

[0360] Referring to the synthesis method of Example 22, the starting materials in the following table are used in steps 1 and 2 to obtain a borate intermediate, and then reacted with compound 2 according to step 3 to obtain the corresponding compound in the following table:

[0361]

[0362]

[0363] Referring to Example 22, the method of steps 1 and 2 was used to obtain the borate ester intermediate, and then referring to the method of steps 3 and 4 of Example 7, the corresponding compounds in the following table were obtained:

[0364]

[0365] Referring to Example 22, the method of steps 1 and 2 was used to obtain the borate ester intermediate, and then referring to the method of steps 3 and 4 of Example 17, the corresponding compounds in the following table were obtained:

[0366]

[0367]

[0368] Referring to the method of step 7 of Example 33, compound 278 was reacted with the starting materials in the following table to obtain the corresponding compounds in the following table:

[0369]

[0370] Referring to the method of Example 22, the starting materials shown in the following table were used instead of 2-methyl-5-bromopyridine to obtain the corresponding compounds shown in the following table:

[0371]

[0372]

[0373]

[0374] Referring to the method starting from step 2 in Example 22, the starting materials in the following table were used to obtain the corresponding compounds in the following table:

[0375]

[0376]

[0377] Referring to the synthesis method of compound 151, (1R, 3R)-3-aminocyclopentanol was substituted for (1S, 3R)-3-aminocyclopentanol hydrochloride in step 1 to obtain intermediate 356-A as shown in the following table. Then referring to the method of Example 22, the starting material in the following table was substituted for 2-methyl-5-bromopyridine to react and intermediate 356-A was substituted for compound 151 in step 3 to obtain the corresponding compound in the following table

[0378]

[0379] Example 23: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(2-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 180)

[0380]

[0381] Step 1: Add sodium hydride (112 mg, 4.67 mmol) to a tetrahydrofuran (20 mL) solution containing 4-pyrazole boric acid naphthalene ester (498 mg, 2.6 mmol). Then add 4-chloro-2-methylpyrimidine (300 mg, 2.3 mmol) and stir at 25 ° C for 3 hours. After the reaction, add water (30 mL), and the mixed solution is extracted with ethyl acetate (30 mL × 3). Combine the organic phases, dry the organic phase with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is purified by silica gel chromatography (dichloromethane / methanol = 9:1) to obtain a white solid (200 mg, yield 28%). (ESI) m / z.287.2.[M+H] + .

[0382] Step 2: According to the method of step 2 of Example 2, the product of step 1 (81 mg, 0.11 mmol) and compound 151 (50 mg, 0.14 mmol) were reacted to obtain yellow solid compound 180 (7 mg, yield 12%). 1 H NMR (400MHz, DMSO-d6) δ9.55 (s, 1H), 8.74 (d, J = 5.6Hz, 1H), 8.58 (s, 1H), 8.43 (s, 1H), 8. 17(brs,1H),7.75(d,J=5.6Hz,1H),7.15(d,J=7.2Hz,1H),6.58(brs,2H),4.62–4.57(m, 1H),4.31–4.27(m,1H),2.84–2.80(m,2H),2.64(s,3H),2.40–2.35(m,1H),2.29–2.22(m ,1H),1.99–1.81(m,2H),1.79–1.66(m,2H),1.33(t,J=7.2Hz,3H).(ESI)m / z.432.2[M+1] + .

[0383] Referring to the method of Example 23, the starting materials shown in the following table were used instead of 4-chloro-2-methylpyrimidine to obtain the corresponding compounds shown in the following table:

[0384]

[0385] Example 24: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-(isopropylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 187)

[0386]

[0387] Step 1: Dissolve tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (1.0 g, 2.65 mmol) in 1,4-dioxane (5 mL), then add a 1,4-dioxane solution of hydrochloric acid (4 M, 10 mL), and stir at 25°C for 1 hour. After the reaction is complete, concentrate under reduced pressure to obtain a white solid compound (650 mg, 88%). (ESI) m / z 278.2.[M+H] + .

[0388] Step 2: Add 2-propanesulfonyl chloride (494 mg, 3.5 mmol) to a solution of 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine (800 mg, 2.9 mmol) and triethylamine (876 mg, 8.7 mmol) in dichloromethane (10 mL). The mixture was stirred at 25°C for 16 hours. After the reaction, water (30 mL) was added, and the mixture was extracted three times with dichloromethane (20 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a yellow oil (400 mg, yield 95%). (ESI) m / z.384.3.[M+H] + .

[0389] Steps 3 and 4: Referring to the method starting from step 3 of Example 17, the product of step 2 (73 mg, 0.19 mmol) was used as the starting material to react with intermediate D (80 mg, 0.16 mmol) to obtain the formate salt of yellow solid compound 187 (30 mg, two-step yield 43%). 1H NMR (400MHz, DMSO-d6) δ8.43(s,1H),8.19(s,1H),8.14(s,1H),8.07(s,1H),7.12(d,J=7.2Hz,1H),6.47(s,2H),4.79(s,1H),4.52-4.46(m 1H),4.44–4.34(m,1H),4.28–4.16(m,1H),3.76(d,J=12.0Hz,2H),3.40(d, J=6.4Hz,1H),3.13(t,J=12.0Hz,2H),2.83–2.77(m,2H),2.32–2.25(m,1H) ,2.15(d,J=12.0Hz,2H),2.09–1.99(m,1H),1.93–1.76(m,4H),1.73–1.61( m,2H),1.31(t,J=7.2Hz,3H),1.25(d,J=6.4Hz,6H).(ESI)m / z.529.3[M+1] + .

[0390] Referring to the method of Example 24, the starting materials shown in the following table were used to react to obtain the corresponding boric acid ester intermediate, which was then reacted with compound 151 to obtain the compound shown in the following table:

[0391]

[0392] Referring to the method of Example 24, the starting materials shown in the following table were used instead of 2-propanesulfonyl chloride to obtain the following compounds:

[0393]

[0394] Example 25: (S)-3-ethyl-8-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N2-(tetrahydrofuran-3-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 259)

[0395]

[0396] Steps 1 and 2: Refer to the synthesis method of intermediate D and use (S)-tetrahydrofuran-3-amine to prepare yellow solid intermediate G (two-step yield 28%). (ESI) m / z.488.0.[M+H] + .

[0397] Step 3: Referring to the method of Step 2 of Example 2, intermediate G (200 mg, 0.41 mmol) was used as the starting material and reacted with tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (186 mg, 0.49 mmol) to obtain intermediate H (280 mg, yield 94%) as a yellow oil.

[0398] (ESI) m / z 659.3.[M+H] + .

[0399] Step 4: Referring to the method of Step 12 in Example 1, intermediate H (280 mg, 0.42 mmol) was used as the starting material to obtain yellow solid compound 259 (88 mg, yield 48%). 1 H NMR (400MHz, DMSO-d6) δ8.34(s,1H),8.18(s,1H),8.03(s,1H),7.25(d,J=5.6Hz,1H),6.39(s,1H),4 .71–4.67(m,1H),4.21–4.01(m,1H),4.04–4.00(m,1H),3.94–3.90(m,1H),3.82–3.76(m,1H),3.74–

[0400] 3.71(m,1H),3.06(d,J=12.0Hz,2H),2.87–2.82(m,2H),2.68–2.59(m,2H),2.54(s,1H),2.33–2.25(m,1H), 2.14–2.06(m,1H),2.02(d,J=12.0Hz,2H),1.84–1.75(m,2H),1.31(t,J=7.2Hz,3H).(ESI)m / z.409.2[M+1] + .

[0401] Referring to the method of Example 25, the starting material 1 in the following table was used to replace (S)-tetrahydrofuran-3-amine to prepare the relevant intermediate, which was then reacted with the starting material 2 to obtain the corresponding compound:

[0402]

[0403] Referring to the method of Example 25, the starting materials in the following table were used instead of (S)-tetrahydrofuran-3-amine to prepare the intermediate 261-A in the following table. Then, referring to the method of Example 11, the intermediate 261-A was reacted with iodomethane to obtain the compound 261 in the following table.

[0404]

[0405]

[0406] Referring to the method of Example 25, the following compounds were prepared by substituting the starting materials in the following table for (S)-tetrahydrofuran-3-amine:

[0407]

[0408] Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with compound 258 to obtain the following compound:

[0409]

[0410] Referring to the synthesis method of compound 250, the starting materials in the following table were used to start the reaction to obtain the following compounds

[0411] Referring to the method of step 2 in Example 6, the starting materials in the following table were reacted with compound 259 to obtain the following compound:

[0412]

[0413] Referring to the synthesis method of compound 225, the starting materials in the following table were substituted for (S)-tetrahydrofuran-3-amine to obtain the following compounds:

[0414]

[0415] Example 26: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-(2-hydroxyethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 207)

[0416]

[0417] Step 1: To a solution of intermediate F (50 mg, 0.10 mmol) in N,N-dimethylformamide (5 mL), tert-butyl (2-iodoethoxy) dimethylsilane (71 mg, 0.25 mmol) and cesium carbonate (161 mg, 0.50 mmol) were added. The mixture was stirred at 45 °C for 12 hours. The reaction mixture was cooled to room temperature, water (1 mL) was added, and the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane: methanol = 3:1) to obtain a yellow solid compound (40 mg, yield 41%). (ESI) m / z 581.3.[M+H] + .

[0418] Step 2: Using the product of step 1 (40 mg, 0.070 mmol) as the starting material, the protecting group was removed by referring to the method of step 4 of example 7 to obtain the formate salt of yellow solid compound 207 (5 mg, yield 31%). 1 H NMR(400MHz,DMSO-d6)δ8.42(s,1H),8.18(s,1H),8.15(brs,2H),8.05(s,1H),7.12( d,J=7.2Hz,1H),6.42(brs,2H),4.47–4.45(m,1H),4.19–4.15(m,2H),3.55–3.52(m, 2H),3.06–3.03(m,2H),2.80–2.75(m,2H),2.55–2.50(m,4H),2.40–2.26(m,2H),2.1 4–1.92(m,6H),1.83–1.81(m,2H),1.72–1.59(m,2H),1.30(t,J=7.2Hz,3H).(ESI)m / z 467.2

[0419] [M+1] + .

[0420] Referring to the method of Example 26, the starting materials in the following table were used instead of intermediate F to prepare the corresponding compounds in the following table:

[0421]

[0422] Example 27: (S)-3-ethyl-8-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N2-(tetrahydrofuran-3-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 230)

[0423]

[0424] Referring to the method of step 12 of Example 1, intermediate G (588 mg, 1.2 mmol) was used to prepare yellow solid compound intermediate I (350 mg, yield 86%). (ESI) m / z 338.1.[M+H] + .

[0425] Referring to the method of step 2 of Example 2, the starting materials in the following table and the compound intermediate I were reacted to obtain the corresponding compound

[0426]

[0427] Referring to the method starting from step 3 in Example 17, the starting materials in the following table were reacted with intermediate G to obtain the corresponding compound

[0428]

[0429] Example 28: 3-((5-amino-3-ethyl-8-(1-(1'-ethyl-[1,4'-bipiperidinyl]-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclohexan-1-ol (Compound 246)

[0430]

[0431] Referring to the method of Example 25, 3-aminocyclohexanol was used instead of (S)-tetrahydrofuran-3-amine to prepare intermediate J, and then referring to the method of Step 2 of Example 6 to obtain the formate salt of compound 246. 1 H NMR(400MHz,DMSO-d6)δ8.47(s,1H),8.22–8.17(m,4H),8.02(s,1H),6.87( d,J=7.6Hz,1H),6.36(brs,2H),4.63–4.56(m,1H),4.16–4.13(m,1H),4.08( s,1H),3.12–2.93(m,6H),2.80(q,J=7.2Hz,2H),2.35–2.27(m,4H),2.11–1. 41(m,18H),1.29(t,J=7.2Hz,3H),1.08–1.01(m,3H).(ESI)m / z548.3.[M+1] + .

[0432] Example 29: 3-ethyl-8-(4-(4-(4-ethylpiperazin-1-yl)piperidin-1-yl)-3-methoxyphenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 315)

[0433]

[0434] Step 1: Add cesium acetate (28g, 87mmol) and Pd2(dba)3 (4.0g, 4.3mmol) and BINAP (5.4g, 8.7mmol) to a mixture of 1,4-dioxane (200mL) containing 1-ethyl-4-(piperidin-4-ylmethyl)piperazine (8.0g, 40mmol) and 1-bromo-4-chloro-2-methoxybenzene (9.6g, 43mmol). The mixture was stirred at 100°C for 12 hours under nitrogen protection. The reaction temperature was cooled to room temperature and water (100mL) was added. The mixed solution was extracted three times with ethyl acetate (200mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 4:1) to obtain a yellow oil (7.0g, yield 52%). (ESI)m / z338.2[M+H] + .

[0435] Step 2: Potassium acetate (5.1 g, 62 mmol), Pd2(dba)3 (1.2 g, 2.1 mmol) and X-Phos (2.0 g, 4.1 mmol) were added to a mixture of 1,4-dioxane (100 mL) containing 1-(1-(4-chloro-2-methoxyphenyl)piperidin-4-yl)-4-ethylpiperazine (7.0 g, 21 mmol) and bisvaleryl diboron (7.9 g, 31 mmol). The mixture was stirred at 100 °C for 12 hours under nitrogen protection. The reaction mixture was cooled to room temperature and water (100 mL) was added. The mixture was extracted three times with ethyl acetate (300 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 4:1) to obtain yellow oil intermediate K (7.0 g, yield 79%). (ESI) m / z 430.3.[M+H] + .

[0436] Step 3: Add cesium carbonate (2.7 g, 8.0 mmol) and Pd(dppf)Cl2 (0.20 g, 0.20 mmol) to a mixture of 1,4-dioxane / water (8 mL, 4 / 1) containing 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (1.4 g, 3.0 mmol) and intermediate K (4.0 g, 7.97 mmol). The mixture was reacted in a microwave at 100°C for 1 hour under nitrogen protection. The reaction was cooled to room temperature and water (50 mL) was added. The mixture was extracted three times with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 10:1) to obtain a yellow solid (900 mg, yield 42%). (ESI) m / z 725.4. [M+H] + .

[0437] Step 4: A solution of N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(4-(4-(4-ethylpiperazin-1-yl)piperidin-1-yl)-3-methoxyphenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (900 mg, 1.2 mmol) in trifluoroacetic acid / dichloromethane (5 mL, 3 / 1) was stirred at 25°C for 3 hours. After the reaction was completed, diisopropylethylamine (10 mL) was added to quench the reaction and the mixture was concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to give a yellow solid compound 315 formate (255 mg, yield 35%). 1 H NMR (400MHz, DMSO-d6) δ8.14(brs,1H),7.91(s,1H),7.25–7.17(m,2H),7.09(d,J=8.0Hz,1H),6. 91(d,J=8.0Hz,1H),6.62(brs,2H),4.14–4.10(m,1H),3.91(d,J=8.0Hz,2H),3.82(s,3H),3.48( d,J=12.0Hz,3H),3.26–3.24(m,2H),2.82–2.78(m,2H),2.61–2.51(m,6H),2.49–2.44(m,6H),1. 88–1.84(m,4H),1.64–1.60(m,4H),1.31(t,J=7.2Hz,3H),1.14(t,J=7.2Hz,3H).(ESI)m / z.575.3

[0438] [M+1] + .

[0439] Referring to the method of Example 29, the starting materials in the following table were used instead of 1-ethyl-4-(piperidin-4-ylmethyl)piperazine to react to obtain the corresponding intermediate, and then reacted with compound 2 according to the method of step 3 of Example 29 to obtain the following corresponding compound:

[0440]

[0441] Referring to the method of Example 29, the starting material 1 was used to replace 1-ethyl-4-(piperidin-4-ylmethyl)piperazine, and the starting material 2 shown in the following table was used to replace 1-bromo-4-chloro-2-methoxybenzene to react to obtain the corresponding compound:

[0442]

[0443] Referring to the method of steps 1 and 2 of Example 29, the starting materials in the following table were used instead of 1-ethyl-4-(piperidin-4-ylmethyl)piperazine to react to obtain the corresponding intermediate, and then referring to the method of steps 3 and 4 of Example 29 to react with intermediate D to obtain the following corresponding compound:

[0444]

[0445] Referring to the method of steps 1 and 2 of Example 29, the starting materials in the following table were used instead of 1-ethyl-4-(piperidin-4-ylmethyl)piperazine to react to obtain the corresponding intermediate, and then referring to the method of step 3 of Example 29 to react with compound 151 to obtain the following corresponding compound:

[0446]

[0447] Referring to the method of step 3 and step 4 of Example 29, the starting materials shown in the following table were reacted to obtain the corresponding compounds:

[0448]

[0449] Referring to the method of Example 29, the starting materials in the following table were reacted with the intermediate K to obtain the corresponding compound

[0450]

[0451]

[0452] Example 30: (1S,3R)-3-((5-amino-3-ethylpyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 263)

[0453]

[0454] According to the method of step 4 of Example 1, compound 151 (100 mg, 0.28 mmol) was used as the starting material to obtain compound 263 (20 mg, 25%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.14(brs,1H),7.75(d,J=6.0Hz,1H),7.01(d,J=7.2Hz ,1H),6.59(d,J=6.0Hz,1H),6.51(brs,2H),4.81(s,1H),4.48–4.44(m,1H),4. 19–4.17(m,1H),2.78–2.73(m,2H),2.18–2.14(m,1H),2.01–1.96(m,1H),1.80 –1.74(m,2H),1.66–1.59(m,2H),1.28(t,J=7.2Hz,3H).(ESI)m / z.274.1[M+1] + .

[0455] Example 31: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentane-1-ol (Compound 269)

[0456]

[0457] Step 1: Add 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (906 mg, 4.6 mmol) and cesium carbonate (2.3 g, 7.0 mmol) to a solution of 4-chloro-5-methylpyrimidine (300 mg, 2.3 mmol) in N,N-dimethylformamide (15 mL). The mixture was stirred at 80 ° C for 12 hours under nitrogen protection. The reaction mixture was cooled to room temperature and water (50 mL) was added. The mixed solution was extracted with ethyl acetate three times (50 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the product (200 mg, yield 30%), which was directly used in the next step. (ESI) m / z.287.2 [M+H] + .

[0458] Steps 2 and 3: Referring to the method of steps 3 and 4 of Example 29, the product of step 1 was reacted with intermediate D to obtain yellow solid compound 269 formate (two-step yield 46%). 1H NMR(400MHz,DMSO-d6)δ9.61(s,1H),8.90(s,1H),8.77(s,1H),8.56(s,1H),8.38(s,1H),8.14(brs ,1H),7.37(d,J=7.2Hz,1H),6.91(s,2H),4.80(s,1H),4.57–4.53(m,1H),4.30–4.25(m,1H),2.86–

[0459] 2.81(m,2H),2.66(s,3H),2.46–2.40(m,2H),2.23–2.13(m,1H),1.93–1.8 3(m,2H),1.74–1.64(m,2H),1.32(t,J=7.2Hz,3H).(ESI)m / z.432.2[M+1] + .

[0460] Referring to the method of Example 31, the starting materials in the following table were used instead of 4-chloro-5-methylpyrimidine to carry out the reaction and the two isomers in the product of step 1 were separated to obtain the corresponding compounds in the following table:

[0461]

[0462] Referring to the method of step 2 of Example 6, the starting materials shown in the following table were used to react to obtain the corresponding compounds shown in the following table:

[0463]

[0464] Referring to the method of Example 31, the starting materials shown in the following table were used instead of 4-chloro-5-methylpyrimidine to carry out the reaction to obtain the corresponding compounds shown in the following table:

[0465]

[0466] Referring to the method of step 1 of Example 31, 4-chloro-5-methylpyrimidine was replaced with the starting material shown in the following table to obtain a boronate intermediate, which was then reacted with compound 151 according to the method of step 2 of Example 2 to obtain the corresponding compound shown in the following table:

[0467]

[0468]

[0469]

[0470] Referring to the method of Example 22, the starting materials in the following table were used instead of 2-methyl-5-bromopyridine to obtain the borate intermediate, and then the method of steps 2 and 3 of Example 31 was used to react with the intermediate D to obtain the corresponding compound in the following table:

[0471]

[0472] Referring to the method of step 1 of Example 23, the starting materials shown in the following table were used to replace 4-chloro-2-methylpyrimidine to obtain intermediate 335-A, and then reacted with intermediate D according to the method of steps 2 and 3 of Example 31 to obtain the corresponding compounds shown in the following table

[0473]

[0474] Referring to the method of step 1 of Example 23, the starting materials shown in the following table were used instead of 4-chloro-2-methylpyrimidine to obtain intermediate 346-A, and then reacting according to the method of steps 3 and 4 of Example 7 to obtain the corresponding compounds shown in the following table:

[0475]

[0476] Example 32: 8-Bromo-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 2)

[0477]

[0478] Referring to the method of step 12 of Example 1, 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (1.0 g, 2.0 mmol) was used as the starting material to obtain yellow solid compound 2 (650 mg, yield 93%). (ESI) m / z 352.0.[M+H] + .

[0479] Referring to the method of Example 23, the starting materials in the following table were reacted with compound 2 to obtain the corresponding compounds in the following table:

[0480]

[0481] Example 33: 3-Ethyl-8-(3-methoxy-4-(4-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 293) and 8-(4-(4-(3,8-diazabicyclo[3.2.1]octan-3-yl)piperidin-1-yl)-3-methoxyphenyl)-3-ethyl-N2-(tetrahydro-2H-pyran-pyridin-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 319)

[0482]

[0483] Step 1 and 2: Referring to the method of step 1 and step 2 of Example 1, tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.5 g, 0.016 mol) and benzyl 4-oxopiperidine-1-carboxylate (5.7 g, 0.025 mol) were used as starting materials to obtain a yellow oil (3 g, two-step yield 61%). (ESI) m / z 296.3.[M+H] + .

[0484] Steps 3 and 4: Referring to the method of steps 1 and 2 of Example 7, tert-butyl 3-(piperidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate was used as the starting material to obtain the brown oil intermediate 293-A (two-step yield 66%). (ESI) m / z 528.3.[M+H] + .

[0485] Steps 5, 6: Referring to the synthesis method of compound 8 as suggested in Example 2, intermediate 293-A was reacted with 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine to obtain yellow solid compound 319 (two-step yield 35%). 1H NMR (400MHz, DMSO-d6) δ8.31 (s, 2H), 7.92 (s, 1H), 7.22–7.18 (m, 2H), 7.01 (d, J = 7.2Hz, 1H), 6. 89(d,J=8.4Hz,1H),6.45(s,2H),4.17–4.07(m,1H),3.92–3.88(m,2H),3.81(s,3H),3.77(s,2H ),3.41(d,J=11.6Hz,3H),3.27(t,J=11.2Hz,3H),2.83–2.74(m,4H),2.60–2.54(m,2H),2.32–2 .29(m,1H),1.88–1.75(m,8H),1.66–1.54(m,4H),1.31(t,J=7.2Hz,3H).(ESI)m / z.573.3[M+1] + .

[0486] Step 7: A solution of compound 319 (100 mg, 0.17 mmol) and formaldehyde (8.0 mg, 0.27 mmol) in methanol (10 mL) was stirred at 25°C for 10 minutes, and then sodium borohydride (20 mg, 0.52 mmol) was added. After stirring at 25°C for 30 minutes, the mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 1:1) to obtain yellow solid compound 293 (40 mg, yield 39%). 1 H NMR (400MHz, DMSO-d6) δ7.92 (s, 1H), 7.27–7.12 (m, 2H), 7.00 (d, J = 7.2Hz, 1H), 6.88 (d, J = 8.0Hz, 1H),6.44(brs,2H),4.19–4.01(m,1H),3.92–3.88(m,2H),3.88(s,3H),3.39(d,J=12.0Hz,2H),3 .30–3.22(m,2H),3.10(s,2H),2.83–2.78(m,2H),2.66–2.54(m,4H),2.38(d,J=8.0Hz,2H),2.22 (d,J=12.0Hz,4H),1.87–1.77(m,6H),1.70–1.50(m,6H),1.31(t,J=7.2Hz,3H).(ESI)m / z.587.3

[0487] [M+1] + .

[0488] Example 34: (1S,3R)-3-((5-amino-3-ethyl-8-(3-methoxy-4-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)phenyl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 312)

[0489]

[0490] Step 1: Add cesium carbonate (5.18 g, 15.0 mmol) and Pd(dppf)Cl2 (0.39 g, 0.50 mmol) to a mixture of tetrahydrofuran / water (50 mL) containing tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (2.0 g, 5.0 mmol) and 1-bromo-4-chloro-2-methoxybenzene (1.8 g, 7.0 mmol). The mixture was stirred at 70 ° C for 1 hour under nitrogen protection. The reaction was cooled to room temperature and water (20 mL) was added. The mixed solution was extracted three times with ethyl acetate (10 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 70% / 30%) to obtain a yellow oil (1.8 g, yield 83%). (ESI) m / z.392.1 [M+H] + .

[0491] Step 2 to Step 5: Referring to the method of Step 4 to Step 7 of Example 33, the product of Step 1 was reacted to obtain yellow solid compound 312 formate (four-step yield 1.3%). 1 H NMR (400 MHz, DMSO-d6)δ

[0492] 8.18(d,J=4.0Hz,3H),8.00(s,1H),7.94(s,1H),7.60(d,J=8.0Hz,1H),7.43(d,J=1.2 Hz,1H),7.31-7.29(m,1H),7.05(d,J=7.2Hz,1H),6.53(s,2H),4.44–4.39(m,1H),4.2 0–4.09(m,2H),3.91(s,3H),2.89(s,2H),2.79(m,2H),2.24(s,3H),2.19–1.98(m,7H) ,1.96–1.91(m,1H),1.84–1.54(m,5H),1.31(t,J=7.2Hz,3H).(ESI)m / z.543.3.[M+H] + .

[0493] Example 35: 3-ethyl-8-(3-methoxy-4-(3-methyl-4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N 2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 287)

[0494]

[0495] Step 1: Referring to the method of step 2 of Example 6, 1-methylpiperazine (1.5 g, 15 mmol) and N-Boc-3-methyl-4-piperidone (3.2 g, 15 mmol) were used as starting materials to obtain white solid intermediate 287-A (2.5 g, yield 53%). (ESI) m / z.298.3[M+1] + .

[0496] Step 2: Referring to the method of step 4 of Example 7, intermediate 287-A (2.5 g, 8.0 mmol) was used as the starting material to obtain white solid intermediate 287-B (1.7 g, yield 87%). (ESI) m / z.198.3[M+1] + .

[0497] Step 3: To a mixture of 1,4-dioxane (10 mL) containing intermediate 287-B (300 mg, 1.5 mmol) and 1-bromo-4-chloro-2-methoxybenzene (336 mg, 1.5 mmol) were added potassium tert-butoxide (438 mg, 4.6 mmol) and tBuXPhos PdG3 (120 mg, 0.15 mmol), tBuXPhos (129 mg, 0.30 mmol). The mixture was stirred at 100 ° C for 1 hour under nitrogen protection and microwave conditions. The reaction was cooled to room temperature and water (30 mL) was added. The mixed solution was extracted three times with ethyl acetate (30 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane / methanol = 70%: 30%) to obtain yellow oil intermediate 287-C (280 mg, yield 54%). (ESI) m / z 338.2.[M+1] + .

[0498] Steps 4 and 5: Intermediate 287-C was reacted with compound 2 according to the method of step 2 of Example 7 to obtain intermediate 287-D, and then intermediate 287-D was reacted with compound 2 according to the method of step 2 of Example 2 to obtain yellow solid compound 287 formate (two-step yield 37%). 1H NMR (400MHz, DMSO-d6) δ8.14(brs,1H),7.91(s,1H),7.22–7.20(m,2H),7.05(d,J=7.2Hz,1H),6. 88–6.85(m,1H),6.55(s,2H),4.14–4.10(m,1H),3.92–3.89(m,2H),3.82(s,3H),3.41–3.37(m,5 H),3.30–3.24(m,5H),2.84–2.78(m,3H),2.54–2.52(m,2H),2.51(s,3H),2.17(s,3H),1.88–1.8 4(m,3H),1.63–1.57(m,3H),1.31(t,J=7.2Hz,3H),1.09(d,J=6.8Hz,3H).(ESI)m / z.575.3[M+1] + .

[0499] Example 36: (1S,3R)-3-((5-amino-3-ethyl-8-(3-methoxy-4-(8-methyl-3,8-diazabicyclo[3.2.1]octyl-3-yl)phenyl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentane-1-ol (Compound 286)

[0500]

[0501] Step 1: Referring to the method of step 1 of Example 7, tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.1 g, 5.2 mmol) was reacted to obtain yellow oil intermediate 286-A (0.97 g, yield 50%). (ESI) m / z.353.3[M+1] + .

[0502] Step 2: Referring to the method of step 4 of Example 7, intermediate 286-A (970 mg, 2.7 mmol) was used as the starting material to obtain white solid intermediate 287-B (450 mg, yield 65%). (ESI) m / z.253.1[M+1] + .

[0503] Step 3: Referring to the method of step 7 of Example 33, intermediate 286-B (450 mg, 1.8 mmol) was used as the starting material to obtain white solid intermediate 286-C (370 mg, yield 74%). (ESI) m / z 267.1.[M+H] + .

[0504] Steps 4 and 5: Intermediate 286-C was reacted with compound 151 according to the method of step 2 of example 7 to obtain intermediate 286-D, and then intermediate 286-D was reacted with compound 151 according to the method of step 2 of example 2 to obtain yellow solid compound 286 (two-step yield 2.8%). 1 H NMR(400MHz, DMSO-d6))δ7.90(s,1H),7.32(d,J=1.6Hz,1H),7.19–7.16(m,1H),7.00(d,J=7 .2Hz,1H),6.81(d,J=8.4Hz,1H),6.41(s,2H),4.75(d,J=3.6Hz,1H),4.42-4.37(m,1H),4.13 (d,J=4.4Hz,1H),3.81(s,3H),3.21–3.06(m,4H),2.85–2.72(m,4H),2.21(s,3H),2.16-2.11 (m,1H),1.96–1.81(m,5H),1.77–1.54(m,4H),1.30(t,J=7.2Hz,3H).(ESI)m / z.504.3.[M+H] + .

[0505] Example 37: 3-ethyl-8-(3-methoxy-4-(4-(3-methyl-3,8-diazabicyclo[3.2.1]octyl-8-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 327)

[0506]

[0507] Step 1 to Step 3: Referring to the method of Step 1 to Step 3 of Example 7, 1,4-dioxa-8-azaspiro[4.5]decane was used to react to obtain yellow solid intermediate 327-A (three-step yield 20%). (ESI) m / z.671.3

[0508] [M+1] + .

[0509] Step 4: A solution of intermediate 327-A (1.0 g, 1.5 mmol) in trifluoroacetic acid / dichloromethane (1 mL / 10 mL) was stirred at 25°C for 1.5 hours. After the reaction was completed, the product was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (1% ammonia methanol solution / dichloromethane = 30% / 70%) to obtain yellow solid intermediate 327-B (750 mg, yield 92%). (ESI) m / z.[M+H] + 521.4.

[0510] Step 5: Add acetic acid (3 mL) to a solution of intermediate 327-B (600 mg, 1.2 mmol) in 6N hydrochloric acid (6 mL), and then stir at 70 ° C for 3 hours. After the reaction is completed, concentrate under reduced pressure, add ammonia methanol solution (20 mL) to alkalize, and concentrate under reduced pressure again. The residue is purified by silica gel chromatography (1% ammonia methanol solution / dichloromethane = 30% / 70%) to obtain yellow solid intermediate L (350 mg, yield 32%). (ESI) m / z. [M+H] + 477.2.

[0511] Step 6: Sodium triacetoxyborohydride (200 mg, 0.90 mmol) was added to a mixture of 1,2-dichloroethane (20 mL) containing intermediate L (150 mg, 0.30 mmol) and 3-methyl-3,8-diazabicyclo[3.2.1]octane (79 mg, 0.60 mmol). The reaction was stirred at 80°C for 16 hours, and the reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The residue was purified by preparative liquid chromatography to give a yellow solid compound 327 formate (17 mg, yield 9%). 1 H NMR (400MHz, DMSO-d6) δ8.20(brs,1.8H),7.92(s,1H),7.26–7.17(m,2H),7.01(d,J=7.2Hz,1H),6.89(d,J=8 .0Hz,1H),6.45(brs,2H),4.14-4.10(m,1H),3.91(d,J=8.4Hz,2H),3.82(s,3H),3.48(s,4H),3.25–3.20(m,2 H),2.80(t,J=7.2Hz,2H),2.64–2.52(m,4H),2.48–2.41(m,4H),2.22(d,J=12.0Hz,2H),1.96(d,J=12.0Hz,2H ),1.86(d,J=12.4Hz,2H),1.75–1.57(m,6H),1.50–1.39(m,2H),1.31(t,J=7.2Hz,3H).(ESI)m / z.587.4[M+H] + .

[0512] Referring to the reductive amination method of step 6 of Example 37, the starting materials in the following table were reacted with the intermediate L to obtain the corresponding compounds in the following table:

[0513]

[0514]

[0515] Example 38: 3-ethyl-8-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)-1,6-naphthyridine-2,5-diamine (Compound 113)

[0516]

[0517] Synthesis of intermediate M: Referring to the synthesis method of steps 1 and 2 of Example 7, 1-methyl-4-(4-piperidinyl)piperazine (5.0 g, 30 mmol) was reacted to obtain yellow solid intermediate M (two-step yield 24%). 1 H NMR (400MHz, CDCl3) δ7.39(d,J=8.0Hz,1H),7.25(s,1H),6.92(d,J=8.0Hz,1H),3.90(s, 3H),2.51–2.34(m,13H),2.34(s,3H),1.89–1.76(m,4H),1.33(s,12H).(ESI)m / z.[M+1] + 416.2.

[0519] Step 1: Add NBS (260 mg, 1.5 mmol) to a solution of 4-amino-2-chloropyridine-3-carboxaldehyde (200 mg, 1.3 mmol) in N,N-dimethylformamide (5 mL). Stir the reaction at 25°C for 5 hours, then pour into water (10 mL). The solid precipitated, filtered and dried to obtain a white solid intermediate 113-A (215 mg, yield 72%). 1 HNMR(400MHz, CDCl3)δ10.39(brs,1H),9.24(s,1H),8.24(s,1H),5.73(s,1H).(ESI)m / z234.9[M+H] +

[0520] Step 2: Add LDA solution (1.9 mL, 3.8 mmol, 2 mol / L) to a solution of ethyl butyrate (440 mg, 3.8 mmol) in tetrahydrofuran (10 mL) at -78 °C. Stir the reaction at -78 °C for 1 hour, then add intermediate 113-A (0.21 g, 0.90 mmol). Stir the reaction at 25 °C for 14 hours. Add saturated ammonium chloride solution (10 mL). The mixture was extracted three times with ethyl acetate (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 10:1) to obtain a white solid intermediate 113-B (88 mg, yield 40%). 1H NMR (400 MHz, DMSO-d6)δ

[0521] 11.51(brs,1H),8.50(s,1H),7.85(s,1H),2.59(dd,J=14.8,7.2Hz,2H),1.19(t,J=7.2Hz,3H).(ESI)m / z 286.9[M+H] +

[0522] Step 3: Referring to the method of step 1 of Example 2, intermediate 113-B (88 mg, 0.31 mmol) was used as the starting material to obtain light yellow solid intermediate 113-C (80 mg, yield 62%). (ESI) m / z 418.0 [M+H] + .

[0523] Step 4: Referring to the method of step 8 of Example 1, intermediate 113-C (80 mg, 0.19 mmol) was used as the starting material to obtain brown solid intermediate 113-D (90 mg, the crude product was directly used in the next step).

[0524] Step 5: A mixture of intermediate 113-D (90 mg) and tetrahydropyran-4-amine (412 mg, 4.1 mmol) was stirred at 145°C for 1 hour. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography (petroleum ether / ethyl acetate = 1:1) to obtain a brown solid intermediate 113-E (60 mg, yield 89%). (ESI) m / z 353.0

[0525] [M+H] + .

[0526] Step 6: Referring to the method of step 2 of Example 2, intermediate 113-E (60 mg, 0.17 mmol) and intermediate M (142 mg, 0.34 mmol) were used as starting materials to react to obtain yellow solid compound 113 formate (23 mg, yield 23%) 1H NMR(400MHz,DMSO-d6)δ8.20(brs,3H),8.00(s,1H),7.81(s,1H),7.23–7.13(m,2H),6.88(d,J=8.0Hz ,1H),6.75(s,2H),6.45(d,J=7.2Hz,1H),4.19–4.11(m,1H),3.92–3.84(m,2H),3.84–3.77(m,3H),3.4 5(d,J=11.2Hz,2H),3.23(t,J=11.2Hz,2H),2.62–2.54(m,6H),2.53–2.51(m,1H),2.48–2.20(m,2H),2 .22(s,3H),1.90–1.76(m,4H),1.65–1.48(m,4H),1.25(dd,J=12.0,4.8Hz,3H).(ESI)m / z.560.3[M+1] + .

[0527] Referring to the synthesis method of step 6 of Example 38, the starting materials in the following table were reacted with the intermediate M to obtain the corresponding compounds in the following table:

[0528]

[0529] Example 39: 3-ethyl-8-(3-methoxyphenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrazino[2,3-d]pyridazine-2,5-diamine (Compound 116)

[0530]

[0531] Step 1: Add iron powder (12 g, 0.21 mol) to a solution of 3,6-dichloro-5-nitropyridazine-4-amine (4.4 g, 21 mmol) in ethanol (40 mL) and saturated ammonium chloride (40 mL). Stir the reaction at 25°C for 18 hours, filter, and wash the filter cake with ethanol (40 mL). Ethanol is evaporated from the filtrate, and the residue is extracted three times with ethyl acetate (100 mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The residue is purified by silica gel chromatography (dichloromethane: methanol = 20:1) to obtain a yellow solid intermediate 116-A (1.8 g, yield 43%). (ESI) m / z 178.9[M+H] +

[0532] Step 2 to Step 4: Follow the method of Step 7 to Step 9 of Example 1 to react with Intermediate 116-A to obtain white solid Intermediate 116-D (three-step yield 2.2%). (ESI) m / z 312.1 [M+H] +

[0533] Step 5: Referring to the method of step 1 of Example 8, intermediate 116-D (66 mg, 0.21 mmol) was reacted to obtain yellow solid intermediate 116-E (60 mg, yield 61%). (ESI) m / z 441.1 [M+H] +

[0534] Step 6: Referring to the method of step 1 of Example 17, intermediate 116-E (50 mg, 0.12 mmol) and trifluoromethanesulfonic anhydride (40 mg, 0.14 mmol) were reacted to obtain yellow solid intermediate 116-E (50 mg, yield 65%).

[0535] (ESI) m / z 573.0[M+H] +

[0536] Step 7 and Step 8: Referring to the method of Step 3 and Step 4 of Example 17, the intermediate 116-E (70 mg, 0.12 mmol) and (3-methoxyphenyl)boronic acid (37 mg, 0.24 mmol) were reacted to obtain a white solid compound 116 formate (5 mg, two-step yield 11%). 1 H NMR (400MHz, DMSO-d6) δ8.23 (s, 1H), 7.73–7.71 (m, 2H), 7.41 (d, J = 7.2Hz, 1H),7.38–7.34(m,1H),7.00–6.97(m,1H),6.70(s,2H),4.16–4.12(m,1H), 3.96–3.92(m,2H),3.82(s,3H),3.42(s,2H),2.90–2.84(m,2H),1.89(d,J =12.0Hz,2H),1.67–1.61(m,2H),1.35–1.31(m,3H).(ESI)m / z.381.1[M+1] + .

[0537] Referring to the synthesis method of Example 39, in step 7, intermediate M is used instead of m-methoxyphenylboronic acid to react to obtain the following compound:

[0538]

[0539]

[0540] Example 40: (1S,3R)-3-((5-amino-3-ethyl-8-(3-methoxy-4-(2-methylpyrimidin-4-yl)phenyl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 288)

[0541]

[0542] Step 1: Referring to the method of step 2 of Example 2, 4-chloro-2-methylpyrimidine (1.0 g, 7.8 mmol) and (4-chloro-2-methoxyphenyl)boronic acid (1.7 g, 9.3 mmol) were reacted to obtain brown solid intermediate 288-A (1.6 g, yield 87%).

[0543] Steps 2 and 3: The intermediate 288-A was reacted with the intermediate according to the method of step 2 of Example 7 to obtain the intermediate, which was then reacted with compound 151 according to the method of step 2 of Example 2 to obtain yellow solid compound 288 formate (two-step yield is about 59%). 1 H NMR (400MHz, DMSO-d6) δ8.67(d,J=5.6Hz,1H),8.14(brs,1H),8.07(s,1H),8.01(d,J=8.4Hz,1H),7.8 7(d,J=5.6Hz,1H),7.58–7.54(m,1H),7.51–7.47(m,1H),7.16(d,J=7.2Hz,1H),6.81(brs,2H),4.87– 4.65(m,1H),4.46–4.38(m,1H),4.17–4.09(m,1H),3.94(s,3H),2.81(q,J=7.2Hz,2H),2.67(s,3H),2 .20–2.11(m,1H),1.97–1.88(m,1H),1.82–1.58(m,4H),1.32(t,J=7.2Hz,3H).(ESI)m / z472.2.[M+1] + .

[0544] Referring to the method of step 1 and step 2 of Example 40, the starting materials in the following table were used to react to obtain the borate intermediate, and then the synthesis method of compound 8 starting from step 2 of the example was reacted with intermediate D to obtain the corresponding compound in the following table

[0545]

[0546] Example 41: cis and trans 4-(4-(5-amino-3-ethyl-2-(((1R,3S)-3-hydroxycyclopentyl)amino)pyrido[3,4-b]pyrazin-8-yl)-1H-pyrazol-1-yl)-1-methylcyclohexan-1-ol (Compounds 284 and 285)

[0547] In the following route, the cis and trans starting materials were reacted to give compounds 284 and 285 respectively.

[0548]

[0549] Step 1: Add isopropylmagnesium chloride (about 5 equivalents) dropwise to a tetrahydrofuran solution of cis- or trans-4-(4-iodo-1H-pyrazol-1-yl)-1-methylcyclohexan-1-ol at 0°C. The mixture is stirred at 0°C for 1 hour under nitrogen protection, and then 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (about 5.5 equivalents) is added. The mixture is stirred at 0°C for 1 hour under nitrogen protection, and then the temperature is raised to 25°C and stirred for 3 hours. After the reaction, the mixture is concentrated under reduced pressure, and the residue is purified by silica gel chromatography (petroleum ether: ethyl acetate = 3:7 to ethyl acetate) to obtain a colorless oil intermediate N (yield of about 72%). (ESI) m / z.307.2.[M+H] + .

[0550] Steps 2 and 3: Intermediate N was reacted with intermediate D according to the method of steps 2 and 3 of Example 31 to obtain compound 284 (two-step yield 30%) and compound 285 (two-step yield 6.5%), both of which were yellow solids. Compound 284: 1 H NMR(400MHz,DMSO-d6)δ8.45(s,1H),8.17–8.13(m,2H),8.01(s,1H),7.28(d,J=6 .8Hz,1H),6.82(s,2H),4.92–4.65(m,1H),4.54–4.46(m,1H),4.26–4.07(m,3H), 2.82(q,J=7.2Hz,2H),2.34–2.27(m,1H),2.12–2.03(m,3H),1.88–1.80(m,4H),1 .71–1.63(m,4H),1.53–1.46(m,2H),1.31(t,J=7.2Hz,3H),1.16(s,3H).(ESI)m / z 452.3.[M+1] + Compound 285: 1 H NMR(400MHz, DMSO-d6)δ8.43(s,1H),8.19(s,2H),8.02(s,1H),7.10(d,J=7.2Hz,1H),6.38(brs,2H),4.50–4.47(m,1H),4.28–4.11(m,2H), 2.80(q,J=7.2Hz,2H),2.35–2.25(m,1H),2.05–2.00(m,3H),2.00–1.52(m,11H),1.30(t,J=7.2Hz,3H),1.19(s,3H).(ESI)m / z.452.3[M+1] + .

[0551] Example 42: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 292)

[0552]

[0553] Step 1: Referring to the method of step 1 of Example 22, 4-(4-iodophenoxy)-1-methylpiperidine (800 mg, 2.5 mmol) and 4-bromo-1H-pyrazole (389 mg, 2.6 mmol) were reacted to give yellow solid intermediate 292-A (410 mg, 48%) (ESI) m / z 336.1 [M+H] + .

[0554] Step 2: At -78°C and nitrogen protection, n-butyl solution (0.5 ml, 2.4 N) was added dropwise to a solution of intermediate 292-A (350 mg, 1.04 mmol) in tetrahydrofuran (10 mL), and then stirred for 20 minutes. A solution of 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (328 mg, 2.08 mmol) in tetrahydrofuran (5 mL) was added. The mixture was stirred at -78°C for 1 hour under nitrogen protection, and then heated to 0°C and stirred for 1 hour. After the reaction was completed, 2 mL of methanol was added to quench the reaction, and the product was concentrated under reduced pressure. The residue was purified by silica gel chromatography (dichloromethane: methanol = 9:1) to obtain a yellow oil intermediate 292-B (150 mg, yield 86%). (ESI) m / z.302.2.[M+H] + .

[0555] Steps 3 and 4: Intermediate 292-B (114 mg, 0.398 mmol) was reacted with intermediate D (100 mg, 0.199 mmol) according to the method of steps 2 and 3 of Example 31 to obtain yellow solid compound 292 formate (38 mg, two-step yield 3.9%). 1HNMR(400MHz,DMSO-d6)δ7.77–7.70(m,2H),7.22–7.15(m,4H),6.91(d,J=8.8Hz,2H ),6.52(d,J=1.6Hz,1H),4.72–4.68(m,1H),4.60–4.54(m,1H),4.09(s,1H),4.00–3 .96(m,1H),3.34–3.20(m,4H),2.79(s,3H),2.73–2.66(m,2H),2.14–1.85(m,5H),1 .76–1.53(m,5H),1.48–1.38(m,1H),1.25(t,J=7.2Hz,3H).(ESI)m / z.529.3.[M+H] + .

[0556] Example 43: (S,E)-N-(1-((2-((4-(5-amino-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4b]pyrazin-8-yl)-2-methoxyphenyl)amino)ethyl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide (Compound 358)

[0557]

[0558] Step 1: Referring to the method of step 2 of Example 6, 4-bromo-2-methoxyaniline (8.0 g, 39 mmol) and tert-butyl (2-oxoethyl)carbamate (6.6 g, 41 mmol) were reacted to obtain yellow solid intermediate 358-A (4.5 g, 30%).

[0559] (ESI) m / z 346.1[M+H] + .

[0560] Steps 2 to 4: Referring to the method of steps 2 to 4 of Example 7, intermediate 358-A was used to react to obtain yellow solid intermediate 358-B (three-step yield 23%). (ESI) m / z.438.2.[M+H] + .

[0561] Step 5: HATU (1.9 g, 5.0 mmol) and triethylamine (0.77 g, 7.7 mmol) were added to a dichloromethane solution (10 mL) of (E)-4-(dimethylamino)but-2-enoic acid (500 mg, 3.9 mmol) and (2S)-2-(methylamino)propionic acid tert-butyl ester (678 mg, 4.3 mmol). The mixture was stirred at 25°C for 4 hours and concentrated under reduced pressure after the reaction. The residue was purified by silica gel chromatography (methanol (containing 1% ammonia water) / dichloromethane = 0% to 100% in 20 minutes) to give a yellow solid intermediate 358-C (980 mg, yield 84%). (ESI) m / z.271.1.[M+H] + .

[0562] Step 6: Referring to the method of step 1 of Example 24, intermediate 358-C (500 mg, 1.9 mmol) was used to react to obtain yellow solid intermediate 358-D (350 mg, yield 88%). (ESI) m / z.215.1.[M+H] + .

[0563] Step 7: Referring to the method of step 1 of this example, intermediate 358-D (62 mg, 0.29 mmol) and intermediate 358-B (120 mg, 0.27 mmol) were reacted to obtain yellow solid compound 358 (18.5 mg, yield 11%). 1 HNMR(400MHz,DMSO-d6)δ8.17(s,2H),7.98(s,1H),7.88(s,1H),7.15(d,J=6.0Hz,2H),6.98(d,J=7.2Hz,1H), 6.67–6.59(m,2H),6.52(s,1H),6.42(s,2H),5.04–5.00(m,2H),4.22–4.11(m,1H),3.96–3.87(m,2H),3.81(s, 3H),3.31–3.28(m,3H),3.16–3.12(m,2H),3.10–3.00(m,2H),2.90(s,2H),2.80–2.75(m,3H),2.16–2.10(m,6 H),1.87–1.84(m,2H),1.63–1.60(m,2H),1.31(t,J=7.2Hz,1H),1.23(d,J=7.2Hz,1H).(ESI)m / z.634.3.[M+H] + .

[0564] Biological test example 1 FLT3 kinase in vitro inhibitory activity experiment:

[0565] Reagents and consumables

[0566] Reagent name Suppliers Part Number batch number FLT3 Carna 08-145 10CBS-0917U Kinase substrate 2 GL 112394 P191104-TL112394 384-well plate Corning 3573 12619003

[0567] instrument

[0568] Centrifuge (manufacturer: Eppendorf, model: 5430), microplate reader (manufacturer: Perkin Elmer, model: Caliper EZ ReaderⅡ), Echo 550 (manufacturer: Labcyte, model: Echo550)

[0569] Experimental methods

[0570] 1. Kinase reaction process

[0571] (1) Prepare 1× Kinase buffer.

[0572] (2) Preparation of compound concentration gradient: The starting concentration of the test compound is 1 μM, 3-fold dilution, 10 concentrations, and single-well detection. Gradient dilution is performed in a 384-well plate to form 10 solutions with different concentrations of 100 times the final concentration. Then 250 nl is transferred to the 384 reaction plate using Echo550 for later use. 250 nl of 100% DMSO is added to the negative control well and the positive control well, respectively.

[0573] (3) Use 1× Kinase buffer to prepare a kinase solution with a final concentration of 2.5 times.

[0574] (4) Add 10 μL of kinase solution at 2.5 times the final concentration to the compound wells and positive control wells respectively; add 10 μL of 1× Kinase buffer to the negative control wells.

[0575] (5) Centrifuge at 1000 rpm for 30 seconds, shake to mix, and incubate at room temperature for 10 minutes.

[0576] (6) Use 1× Kinase buffer to prepare a mixed solution of ATP and Kinase substrate 2 at 25 / 15 times the final concentration.

[0577] (7) Add 15 μL of a mixed solution of ATP and substrate at 25 / 15 times the final concentration to start the reaction.

[0578] (8) Centrifuge the 384-well plate at 1000 rpm for 30 seconds, shake to mix, and incubate at room temperature for 30 minutes.

[0579] (9) Add 30 μL of stop detection solution to stop the kinase reaction, centrifuge at 1000 rpm for 30 seconds, and shake to mix.

[0580] (10) Read the conversion rate using Caliper EZ ReaderⅡ.

[0581] 2. Data Analysis

[0582] Calculation formula

[0583]

[0584] Where: Conversion%_sample is the conversion rate reading of the sample; Conversion%_min: negative control well.

[0585] Biological test example 2: MV4;11 in vitro reproduction inhibition experiment:

[0586] Experimental Materials:

[0587] MV4;11 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences, IMDM medium (Gibco, catalog number 12440), fetal bovine serum (Gibco, catalog number 10099141C), penicillin-streptomycin double antibody (Gibco, catalog number 15140122), DMSO (Sigma, catalog number D2650), Celltiter-Glo detection kit (CTG) (Promega, catalog number G7573), 384-well transparent flat-bottom black-walled cell culture plates (Corning, catalog number 3764), D300e plate reader (Tecan, catalog number D300e), SpectraMax i3x microplate reader

[0588] (MOLECULAR DEVICES, catalog number i3x)

[0589] Experimental methods:

[0590] Cell culture:

[0591] The culture conditions of MV4;11 cells are IMDM, 10% fetal bovine serum, 1% penicillin-streptomycin double antibody, and the cell density does not exceed 1.0*10E6 cells per milliliter, ensuring that it is always in the logarithmic growth phase and the cell viability is greater than 95%.

[0592] Compound preparation:

[0593] The test compound was diluted 3-fold with DMSO starting from 10uM, for a total of 9 concentrations. 60nl of the diluted compound was added to the cell culture plate and a triplicate experiment was set up.

[0594] Compound treated cells:

[0595] The prepared MV4;11 cell suspension was added to a 384-well plate, with 20 μl of cell suspension per well, i.e., each well contained 2,000 MV4;11 cells, so that the final concentration of DMSO was 0.3%. The cell culture plate was placed in a 37°C, 5% carbon dioxide incubator for 72 hours.

[0596] Add 20 μl of Promega CellTiter-Glo reagent to each well of the cell culture plate and incubate at room temperature for 10 minutes with shaking to allow the luminescent signal to stabilize. Read using a SpectraMax i3x microplate reader.

[0597] Data Analysis:

[0598] The raw data were converted into inhibition rate, and the IC50 value (half maximal inhibitory concentration) of the compound was obtained by nonlinear four-parameter curve fitting.

[0599] The following table records the test results in Biological Test Example 1 and Biological Test Example 2. The results show that the exemplary compounds of the present invention have a strong inhibitory effect on FLT3 kinase and have excellent inhibitory activity on MV4;11 cell proliferation.

[0600] A: IC50≤10nM;

[0601] B:10nM <IC50≤100nM;

[0602] C:100nM <IC50≤500nM;

[0603] D:>500nM

[0604] The activity test results of some compounds are shown in the following table.

[0605]

[0606]

[0607]

[0608]

[0609]

[0610]

[0611]

[0612] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A compound as shown in the following formula II, or a pharmaceutically acceptable salt or deuterated product thereof: in, X, Y and Z are each independently selected from the group consisting of N or CR; Ra is selected from the following group: H, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), substituted or unsubstituted 5-9 membered heteroaromatic ring (including monocyclic or condensed ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 3-8 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen (which is a saturated or partially unsaturated heterocycle, preferably a substituted or unsubstituted C3-C6 cycloalkyl, a substituted or unsubstituted 3-6 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen), or substituted or unsubstituted -[L] m -H group; wherein each L is independently selected from the following group: -CH2-, -O-, -NH- or -S-; m is selected from the group consisting of 1, 2, 3, 4, 5 or 6; U is selected from the group consisting of a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-; Rc is selected from the following groups: H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), substituted or unsubstituted 3-8 membered heterocycle (saturated or partially unsaturated, including monocyclic, condensed, bridged or spirocyclic) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C6-C 10 aryl, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, or a substituted or unsubstituted -[L] m -H group; wherein each L is independently selected from the following group: -CH2-, -O-, -NH- or -S-; Re is selected from the group consisting of halogen, -NHR, -OR, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkyl-NH-, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), or substituted or unsubstituted -[L] m -H group; wherein each L is independently selected from the following group: -CH2-, -O-, -NH- or -S-; W is selected from the group consisting of H, -NHR, -OR, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C3-C8 carbocycle (including saturated or partially unsaturated), substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 4-15 membered heterocyclic ring (saturated or partially unsaturated ring, including monocyclic, condensed, bridged or spirocyclic ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring (including monocyclic or condensed ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl (including monocyclic, fused, bridged or spirocyclic), substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide; The W group is substituted by at least one group having a -MA structure, and the M is selected from the following group: a chemical bond, or -CHR-, a carbonyl group, S, O, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-; The A is selected from the following groups: H, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 4-12 membered heterocyclic ring (which is a saturated or partially unsaturated ring, including a monocyclic ring, a condensed polycyclic ring, a bridged ring or a spirocyclic ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring (including a monocyclic ring or a condensed ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C4 alkyl-SO-; In the group A, the substitution refers to substitution by one or more groups selected from group B, and the group B includes: H, halogen, =O, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 3-12 membered (preferably 5-7 membered) heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C4 alkyl-SO-; and in the group B, the substitution refers to substitution by one or more R groups; R is a group selected from the following group: H, halogen, cyano, amino, nitro, hydroxyl, mercapto, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 Ester group, substituted or unsubstituted C6-C 10 Aryloxy, substituted or unsubstituted C1-C6 amide, substituted or unsubstituted C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C4 alkyl-SO-; Unless otherwise specified, in the above formulae, the substitution refers to the substitution of hydrogen atoms on the corresponding groups by one or more substituents selected from the group consisting of deuterium, tritium, halogen, hydroxyl, carboxyl, mercapto, benzyl, C1-C 12 Alkoxycarbonyl, C1-C6 aldehyde, amino, C1-C6 amide, nitro, cyano, unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C3-C8 cycloalkyl, C2-C 10 Alkenyl, C1-C6 alkoxy, C1-C6 alkyl-amino, C6-C 10 aryl, five-membered or six-membered heteroaryl, five-membered or six-membered non-aromatic heterocyclic group, -O-(C6-C 10 aryl), -O-(five-membered or six-membered heteroaryl), C1-C 12 Alkylaminocarbonyl, unsubstituted or halogenated C2-C 10 Acyl, sulfonyl (-SO2-OH), phosphoryl (-PO3-OH), unsubstituted or halogenated C1-C4 alkyl-S(O)2-, unsubstituted or halogenated C1-C4 alkyl-SO-.

2. The compound according to claim 1, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound has a structure shown in the following formula IIa: Wherein, the W ring is selected from the following group: substituted or unsubstituted C6-C 10 aryl, substituted or unsubstituted 4-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl; wherein, in the W group, the substitution refers to substitution by one or more groups selected from group A.

3. The compound according to claim 2, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The W ring is a substituted or unsubstituted ring structure selected from the following group: phenyl, cyclopentyl, cyclohexyl, 4. The compound according to claim 2, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The W ring is a substituted or unsubstituted cyclic structure selected from the following group: phenyl, 5. The compound according to claim 2, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound has a structure shown in the following formula III: wherein the A ring is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl; M is selected from the following group: a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-.

6. The compound according to claim 5, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound has a structure shown in the following formula: in, Rf is selected from the following group: H, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy; t is 0, 1, 2, 3, or 4; The A ring is selected from the following groups: a substituted or unsubstituted 5-12 membered saturated ring (including a spiro ring and a bridged ring), a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 The A ring has at least one heteroatom selected from N or O.

7. The compound according to claim 5, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound has a structure shown in the following formula: in, Rf is selected from the group consisting of H, halogen, cyano, amino, nitro, hydroxyl, thiol, aldehyde, carboxyl, sulfonyl, C1-C4 alkyl-S(O)2-, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy; t is 0, 1, 2, 3, or 4; L is N or CH; The A ring is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C3-C 12 Cycloalkyl, substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C6-C 10 Aryl.

8. The compound according to claim 5, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound has a structure shown in the following formula IV: wherein the A ring is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted -C1-C6 alkyl-phenyl, substituted or unsubstituted C3-C 12 Cycloalkyl; M is selected from the following group: a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-; Ring B is selected from the following groups: a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C6-C 10 Aryl, substituted or unsubstituted C3-C 12 Carbon ring; V is selected from the following group: a chemical bond, or -O-, -CHR-, carbonyl, S, -NH-, -NHC(O)-, -NHS(O)2-, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O)2-.

9. The compound according to claim 5, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The A ring has at least one substituent G, and the G group is selected from the following groups: amino, =O, a substituted or unsubstituted 4-7 membered heterocycle containing 1-3 heteroatoms selected from oxygen and nitrogen, a substituted or unsubstituted C2-C 10 Acyl, substituted or unsubstituted C2-C 10 an ester group, or a substituted or unsubstituted C1-C6 amide group.

10. The compound according to claim 1, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound has a structure selected from the group consisting of:

11. The compound according to claim 1, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: Re is selected from the group consisting of an amine group, and a substituted or unsubstituted C1-C6 alkyl-NH- group.

12. The compound according to claim 1, or a pharmaceutically acceptable salt or deuterated product thereof, characterized in that: The compound is selected from the compounds described in Table 1 of the specification.

13. A pharmaceutical composition, characterized in that The pharmaceutical composition contains a therapeutically effective amount of the compound according to claim 1, one or more of its pharmaceutically acceptable salts, racemates, R-isomers and S-isomers, stereoisomers or tautomers, and one or more pharmaceutically acceptable carriers, excipients, adjuvants, auxiliary materials and / or diluents.

14. Use of the compound according to claim 1, its racemate, R-isomer, S-isomer or pharmaceutically acceptable salt in the preparation of a medicament for treating or preventing a disease associated with abnormal gene level or abnormal expression of a kinase selected from the following group (such as corresponding nucleic acid mutation, deletion, or ectopic or fusion or overexpression of the kinase): FLT3, ALK, RET, ROS, AXL, EGFR.

15. The use according to claim 14, characterized in that The disease is selected from the following group: acute myeloid leukemia, neurofibromatosis type I, multiple myeloma, malignant glioma, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, cervical cancer, lymphoma, bone metastasis, hormone-refractory prostate cancer, hormone-dependent prostate cancer, thyroid tumor, medullary thyroid cancer, mesothelioma, glioblastoma, metastatic carcinoma to the bone, Merkel cell carcinoma, genitourinary tract tumors, Merkel cell carcinoma, bladder cancer, papillary thyroid carcinoma, breast cancer, soft tissue sarcoma, glioma, neuroendocrine tumor, renal cell carcinoma , advanced solid tumors, undifferentiated astrocytic carcinoma, gastrointestinal stromal tumors, Hippel-Lindau syndrome, small cell lung cancer, pancreatic cancer, pancreatic endocrine cancer, central nervous system tumors, metastatic renal cancer, endometrioid carcinoma, endometrioid adenocarcinoma, lung cancer, colorectal cancer, ovarian cancer, rhabdomyosarcoma, melanoma, retinoblastoma, central and peripheral nervous system tumors, acute leukemia, chronic leukemia, bile duct cancer, bronchial cancer, esophageal cancer, testicular cancer, skin cancer, oral cancer, neuroblastoma, anaplastic large cell lymphoma.